CONTACT

FAQ

Biosafety Act No 2of 2009 - as Plain Text by MWakili

LAWS OF KENYA BIOSAFETY ACT No.

2 of 2009 Revised Edition 2012 [2009] Published by the National Council for Law Reporting with the Authority of the Attorney-General www.kenyalaw.org [Rev.

2012] No.

2 of 2009 Biosafety NO.

2 OF 2009 BIOSAFETY ACT ARRANGEMENT OF SECTIONS PART I PRELIMINARY Section 1.

Short title and commencement.

Interpretation.

Scope of the Act.

Objects of the Act.

PART II ESTABLISHMENT, POWERS AND FUNCTIONS OF THE AUTHORITY 5.

Establishment of the Authority.

Board of the Authority.

Objects and functions of the Authority.

Powers of the Board.

Conduct of business and affairs of the Board.

10.

Delegation by the Board.

11.

Remuneration of members of the Board.

12.

The Chief Executive Officer.

13.

Functions of the Chief Executive Officer.

14.

Staff of the Authority.

15.

The common seal of the Authority.

16.

Protection from personal liability.

17.

Liability for damages.

PART III APPLICATIONS FOR APPROVAL AND RISK ASSESSMENT 18.

Application for contained use activity.

19.

Application to introduce into the environment.

20.

Application for importation.

21.

Application for placing on the market.

22.

Genetically modified organisms in transit.

23.

Application to export.

24.

Withdrawal of application.

25.

Confidential information.

26.

Acknowledgement of application.

27.

Risk assessment and risk management.

28.

Non-assessment of risks.

29.

Determination of an application.

30.

Communication of decision.

31.

Suspension or revocation of an approval.

32.

3 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety PART IV REVIEWS AND APPEALS Section 33.

Review of decision.

34.

Offence of withholding information.

35.

Establishment of the Appeals Board.

36.

Powers of the Appeals Board.

37.

Provisions as to the Appeals Board.

PART V REGULATORY AGENCIES 38.

Consultation with regulatory agencies.

39.

Unintentional release into the environment.

PART VI RESTORATION AND CESSATION ORDERS 40.

Environmental restoration order.

41.

Contents of restoration order.

42.

Cessation orders.

PART VII INSPECTION AND MONITORING 43.

Appointment of biosafety inspectors.

44.

Functions of biosafety inspectors.

45.

Powers of biosafety inspectors.

PART VIII FINANCIAL PROVISIONS 46.

Funds of the Authority.

47.

Annual estimates.

48.

Accounts and audit.

49.

Investment of funds.

PART IX MISCELLANEOUS 50.

Handling, packaging, etc., of genetically modified organisms.

51.

Regulations.

52.

Offences and penalties.

53.

Restriction on institution of proceedings.

54.

Public awareness and participation.

55.

Transitional provisions.

SCHEDULES FIRST SCHEDULE REGULATORY AGENCIES SECOND SCHEDULE PROVISIONS AS TO THE CONDUCT OF BUSINESS AND AFFAIRS OF THE BOARD THIRD SCHEDULE INFORMATION REQUIRED IN APPLICATIONS FOR APPROVAL OF CONTAINED USE ACTIVITY FOURTH SCHEDULE INFORMATION REQUIRED IN APPLICATIONS FOR APPROVAL OF RELEASE INTO THE ENVIRONMENT, IMPORTATION OR PLACING ON THE MARKET OF GENETICALLY MODIFIED ORGANISMS FIFTH SCHEDULE PROVISIONS ON RISK ASSESSMENT SIXTH SCHEDULE PROVISIONS AS TO THE APPEALS BOARD [Issue 1] 4 [Rev.

2012] No.

2 of 2009 Biosafety NO.

2 OF 2009 BIOSAFETY ACT [Date of assent: 12th February, 2009.] [Date of commencement: 1st July, 2011.] An Act of Parliament to regulate activities in genetically modified organisms, to establish the National Biosafety Authority, and for connected purposes [L.N.

71/2011.] PART I PRELIMINARY 1.

Short title and commencement This Act may be cited as the Biosafety Act, 2009 and shall come into operation 1 July, 2011.

Interpretation In this Act, unless the context otherwise requires applicant means a person submitting an application pursuant to the provisions of this Act; Authority means the National Biosafety Authority established under section 5; biosafety means the avoidance of risk to human health and safety, and the conservation of the environment, as a result of the use of genetically modified organisms; contained use means any activity undertaken within a facility, installation or other physical structure which involves genetically modified organisms that are controlled by specific measures; environment includes the physical factors of the surroundings of human beings, including land, water, atmosphere, soil, vegetation, climate, sound, odour, aesthetics, fish and wildlife; financial year means the period of twelve months ending on the thirtieth June in each year; genetically modified organism means any organism that possesses a novel combination of genetic material obtained through the use of modern biotechnology techniques; intentional introduction into the environment means any deliberate use of genetically modified organisms other than not contained use; Minister means the Minister for the time being responsible for matters relating to science and technology, 5 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety modern biotechnology includes the application of (a) in-vitro nucleic acid techniques including the use of recombinant deoxyribonucleic acid (DNA) and direct injection of nucleic acid into cells or organelles; or (b) fusion of cells beyond the taxonomic family, that overcome natural physiological, reproductive and recombination barriers and which are not techniques used in traditional breeding and selection; placing on the market means making a genetically modified organism available for sale; and regulatory agency means a regulatory agency as set out in the First Schedule to the Act, or such other agency as the Minister may, by Order in the Gazette, determine.

Scope of the Act (1) The requirements of this Act are in addition to the requirements imposed by any other Act.

(2) This Act shall not apply to genetically modified organisms that are pharmaceuticals for human use.

Objects of the Act The objects of this Act are (a) to facilitate responsible research into, and minimize the risks that may be posed by, genetically modified organisms; (b) to ensure an adequate level of protection for the safe transfer, handling and use of genetically modified organisms that may have an adverse effect on the health of the people and the environment; and (c) to establish a transparent, science-based and predictable process for reviewing and making decisions on the transfer, handling and use of genetically modified organisms and related activities.

PART II ESTABLISHMENT, POWERS AND FUNCTIONS OF THE AUTHORITY 5.

Establishment of the Authority (1) There is established an Authority to be known as the National Biosafety Authority.

(2) The Authority is a body corporate with perpetual succession and a common seal and shall, in its corporate name, be capable of (a) suing and being sued; (b) taking, purchasing or otherwise acquiring, holding, charging or disposing of moveable and immovable property; (c) entering into contracts; and [Issue 1] 6 [Rev.

2012] No.

2 of 2009 Biosafety (d) doing or performing all other things or acts necessary for the proper performance of its functions under this Act, which may lawfully be done or performed by a body corporate.

Board of the Authority (1) The Authority shall be managed by a Board comprising of (a) a chairperson, who shall be an eminent scientist, appointed by the Minister; (b) the Permanent Secretary in the Ministry for the time being responsible for science and technology; (c) the Permanent Secretary in the ministry for the time being responsible for finance; (d) the Permanent Secretary of the Ministry for the time being responsible for agriculture; (e) the Director-General of the National Environment Management Authority; (f) the Managing Director of the Kenya Bureau of Standards; (g) the Managing Director of the Kenya Plant Health Inspectorate Services; (h) the Director of the Department of Veterinary Services; (i) the Secretary of the National Council for Science and Technology; (j) the Chief Public Health Officer; (k) six other persons appointed by the Minister, of whom at least two shall be of either gender and of whom (i) three shall be experts in the following respective sciences, namely biological, environmental and social sciences; (ii) one shall represent interests of consumers; (iii) one shall represent the interests of farmers; (iv) one shall represent the interests of the biotechnology industry; and (l) a Chief Executive officer appointed under section 12, who shall be the Secretary to the Board.

(2) The members of the Board appointed under paragraphs (b) to (j) of subsection (1) may attend in person or designate a representative to attend on their behalf.

(3) The appointment of the chairperson and the members under paragraphs (k) and (l) of subsection (1) shall be by name and by notice in the Gazette.

(4) The chairman and members of the Board, other than the ex-officio members, shall hold office for a period of three years but shall be eligible for reappointment for a further term of three years.

7 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety 7.

Objects and functions of the Authority (1) The object and purpose for which the Authority is established is to exercise general supervision and control over the transfer, handling and use of genetically modified organisms with a view to ensuring (a) safety of human and animal health; (b) provision of an adequate level of protection of the environment.

(2) Without prejudice to the generality of subsection (1), the Authority shall (a) consider and determine applications for approval for the transfer, handling and use of genetically modified organisms, and related activities in accordance with the provisions of this Act; (b) co-ordinate, monitor and assess activities relating to the safe transfer, handling and use of genetically modified organisms in order to ensure that such activities do not have adverse effect on human health and the environment; (c) co-ordinate research and surveys in matters relating to the safe development, transfer, handling and use of genetically modified organisms, and to collect, collate and disseminate information about the findings of such research, investigation or survey; (d) identify national requirements for manpower development and capacity building in biosafety; (e) advise the Government on legislative and other measures relating to the safe transfer, handling and use of genetically modified organisms; (f) promote awareness and education among the general public in matters relating to biosafety; and (g) establish and maintain a biosafety clearing house to serve as a means through which information is made available facilitate the exchange of scientific, technical, environmental and legal information on, and experience with, living modified organisms; (h) perform any other function which is incidental to the performance of any of the foregoing functions.

Powers of the Board The Board shall have all the powers necessary for the proper performance of the functions of the Authority under this Act and, in particular but without prejudice to the generality of the foregoing, the Board shall have power to (a) enter into contracts; (b) manage, control and administer the assets of the Authority in such manner and for such purposes as best promote the purpose for which the Authority is established; (c) receive any gifts, grants, donations or endowments made to the Authority or any other moneys in respect of the Authority and make disbursements therefrom in accordance with the provisions of this Act; [Issue 1] 8 [Rev.

2012] No.

2 of 2009 Biosafety (d) enter into association with such other bodies or organizations within or outside Kenya as it may consider desirable or appropriate and in furtherance of the purposes for which the Authority is established; (e) open a banking account or banking accounts for the funds of the Authority; and (f) offer services to any person upon such terms as the Board may from time to time determine.

Conduct of business and affairs of the Board The business and affairs of the Board shall be conducted in accordance with the Second Schedule.

10.

Delegation by the Board The Board may, by resolution either generally or in any particular case, delegate to a committee or any officer, member of staff or agent of the Board, the exercise of any of the powers or the performance of any of the functions or duties of the Board under this Act.

11.

Remuneration of members of the Board The members of the Board shall be paid such remuneration, fees, allowances and disbursements for expenses as may be approved by the Minister.

12.

The Chief Executive Officer (1) There shall be a Chief Executive Officer of the Board who shall be appointed by the Board.

(2) The Chief Executive Officer shall hold office for such period and on such terms and conditions of employment as the Board may determine.

(3) The Chief Executive Officer shall be an ex-officio member of the Board but shall have no right to vote at any meeting of the Board.

(4) The Chief Executive Officer shall, subject to the direction of the Board, be responsible for the day to day management of the Authority.

13.

Functions of the Chief Executive Officer (1) The Chief Executive Officer shall, subject to the directions of the Board, be responsible for the management of the affairs and transactions of the Authority, the exercise, discharge and performance of its objectives, functions and duties.

(2) The Chief Executive Officer shall (a) ensure the maintenance of efficiency and discipline by all staff of the Authority; (b) manage the budget of the Authority to ensure that its funds are properly expended and accounted for; (c) perform such other duties as the Authority may, from time to time, assign.

9 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety 14.

Staff of the Authority The Board may appoint such officers, agents and other staff of the Authority as are necessary for the proper and efficient discharge of the functions of the Authority under this Act, upon such terms and conditions of service as the Board may determine.

15.

The common seal of the Authority (1) The common seal of the Authority shall be kept in the custody of the Chief Executive Officer or of such other person as the Board may direct, and shall not be used except upon the order of the Board.

(2) The common seal of the Authority, when affixed to a document and duly authenticated, shall be judicially and officially noticed, and unless the contrary is proved, any necessary order or authorisation by the Board under this section shall be presumed to have been duly given.

(3) The common seal of the Authority shall be authenticated by the signature of the chairperson of the Board and the Chief Executive Officer: Provided that the Board shall, in the absence of either the chairperson or the Chief Executive Officer, in any particular matter, nominate one member of the Board to authenticate the seal of the Authority on behalf of either the chairperson or the Chief Executive Officer.

16.

Protection from personal liability No matter or thing done by a member of the Board or by any officer, member of staff, or agent of the Authority shall, if the matter or thing is done bona fide for executing the functions, powers or duties of the Authority under this Act, render the member, officer, employee or agent or any person acting on their directions personally liable to any action, claim or demand whatsoever.

17.

Liability for damages The provisions of section 16 shall not relieve the Authority of the liability to pay compensation or damages to any person for any injury to him, his property or any of his interests caused by the exercise of any power conferred by this Act or any other written law or by the failure, wholly or partially, of any works.

PART III APPLICATIONS FOR APPROVAL AND RISK ASSESSMENT 18.

Application for contained use activity (1) A person shall not conduct any activity involving genetically modified organisms without the written approval of the Authority.

(2) An application for approval to conduct a contained use activity shall (a) be in the prescribed manner; and (b) contain (i) the information set out in the Third Schedule to this Act; and (ii) such other information that the applicant or the Authority may consider necessary for the assessment of the potential risk or benefits of the particular contained use activity.

[Issue 1] 10 [Rev.

2012] No.

2 of 2009 Biosafety 19.

Application to introduce into the environment (1) A person shall not introduce into the environment a genetically modified organism without the written approval of the Authority.

(2) A person wishing to introduce a genetically modified organism into the environment shall submit to the Authority an application describing the activity for which the approval is sought.

(3) An application to introduce a genetically modified organism into the environment shall (a) be in the prescribed manner; (b) contain (i) the information set out in the Fourth Schedule; and (ii) such other information that the applicant or the Authority may consider necessary for the assessment of the potential risk or benefits of the introduction of the particular genetically modified organism into the environment.

(4) The Authority shall publish in the Gazette, at least two newspapers with nationwide circulation, and in an appropriate electronic media, notice concerning any application for release into the environment of a genetically modified organism, for the general information of the public.

(5) Any person may, within thirty days from the date of publication of the notice, make representations to the Authority regarding such an application, and the Authority shall address appropriately any relevant concerns raised by such a person.

20.

Application for importation (1) A person shall not import into Kenya a genetically modified organism without the written approval of the Authority.

(2) An application for importation of a genetically modified organism shall (a) be in the prescribed manner; (b) contain (i) the information set out in the Fourth Schedule; (ii) such other information that the applicant or the Authority may consider necessary for the assessment of the potential risk or benefits of importation of the particular genetically modified organism.

21.

Application for placing on the market (1) A person shall not place on the market a genetically modified organism without the written approval of the Authority.

(2) An application to place on the market a genetically modified organism shall (a) be in the prescribed manner; (b) contain (i) the information set out in the Fourth Schedule; and 11 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety (ii) such other information that the applicant or the Authority may consider necessary for the assessment of the potential risk or benefits of the placement of the particular genetically modified organism on the market.

22.

Genetically modified organisms in transit (1) A person transporting through Kenya genetically modified organisms, which are not destined for use in Kenya shall (a) apply for a written approval of such transportation from the Authority; and (b) ensure that the genetically modified organisms being transported are properly packaged and transported in accordance with such regulations as may be prescribed and any applicable international standards.

(2) An application to transport genetically modified organisms through Kenya shall be in the prescribed manner.

23.

Application to export A person intending to export a genetically modified organism from Kenya shall provide the Authority with an advance written consent granted by a relevant authority of the country to which the genetically modified organism is destined, to the effect that such relevant authority has no objection to the intended exportation.

24.

Withdrawal of application A person applying for any approval may withdraw his application at any time prior to the issuance of a final decision by the Authority.

25.

Confidential information (1) The Authority shall (a) allow an applicant to identify information provided to the Authority in accordance with the requirements of this Act and any regulations made hereunder, that is to be treated as confidential, with justification for claims of confidentiality to be provided upon request; (b) decide whether it accepts as confidential the information designated by the applicant; (c) inform the applicant of any rejection of the claim of confidentiality, providing reasons on request, as well as an opportunity for consultation; and (d) in the event that an applicant withdraws an application in accordance with section 24, respect the applicants claims of confidentiality.

(2) The Authority shall not use confidential information for any purpose not authorized under this Act, and shall ensure that such information is protected by any person involved in handling applications under this Act.

[Issue 1] 12 [Rev.

2012] No.

2 of 2009 Biosafety 26.

Acknowledgement of application (1) Upon receipt of an application, the Authority shall screen the application for completeness and shall, within thirty days from the date of receipt, acknowledge receipt of the application in writing.

(2) Where an application is not complete, the Authority shall request the applicant to submit additional information.

(3) Where the Authority requests for additional information from the applicant, the time taken before getting the information shall not be reckoned by the Authority in calculating the time taken prior to making a final decision on the application.

27.

Risk assessment and risk management (1) Where the application for approval under this Act has been screened and found to be complete, the Authority shall (a) subject to section 28, undertake a risk assessment in terms of the provisions of the Fifth Schedule; and (b) audit risk assessment information submitted by the applicant, if any.

(2) Risk assessment under this section shall be carried out taking into account available information concerning any known risk posed by potential exposure to a genetically modified organism.

(3) Upon completion of the risk assessment, the Authority shall make a report of its findings, and shall indicate any measures to be taken to ensure the safe use of a genetically modified organism.

(4) The Authority shall liaise with the appropriate regulatory agency to ensure that appropriate measures are in place to manage and control risks identified during the risk assessment process.

28.

Non-assessment of risks The Authority may opt not to undertake a risk assessment for purposes of sections 18, 19 and 20, where it determines that sufficient experience or information exists to conclude that the genetically modified organism or contained use activity concerned do not pose a significant risk.

29.

Determination of an application (1) In determining an application, the Authority shall take into account (a) the information submitted by the applicant; (b) such information and conditions as may be submitted by the relevant regulatory agency; (c) the risk assessment report; (d) any relevant representations submitted by members of the public; and (e) socio-economic considerations arising from the impact of the genetically modified organism on the environment, where the decision relates to an application under section 19 of this Act.

13 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety (2) The Authority shall, prior to determining an application, liaise with the relevant regulatory agency, and such regulatory agency shall submit to the Authority any conditions that the regulatory agency considers appropriate to be attached to the approval.

30.

Communication of decision (1) The Authority shall communicate its final decision of approval or rejection of the application to the applicant, within one hundred and fifty days of the receipt of the application but not earlier than ninety days of such receipt.

(2) An approval (a) shall be specific to the activity authorized; and (b) if granted subject to some conditions, including such conditions as may be given by an appropriate regulatory agency, shall clearly state such conditions.

(3) Where an application for approval is rejected, the reasons for such rejection shall be clearly stated.

31.

Suspension or revocation of an approval (1) The Authority may suspend or revoke any approval given under this Act where the person who has been granted such approval is in contravention of any of the conditions imposed on the grant of the approval, or the provisions of this Act.

(2) The Authority shall, before suspending or revoking an approval, give a written notice of its intention to suspend or revoke the approval to the person upon whom it is given, and shall accordingly invite such person to make representations within thirty days from the date of such notice.

(3) Where the Authority suspends or revokes an approval, it shall publish the order suspending or revoking the approval in the Gazette, at least two newspapers with nationwide circulation, and in an appropriate electronic media.

32.

Register The Authority shall maintain a register, which shall contain (a) a copy of (i) every application received; (ii) the risk assessment report; (iii) the decision document; (iv) the approval; and (b) any other information the Authority may consider necessary.

PART IV REVIEW AND APPEALS 33.

Review of decision (1) The Authority may review a decision made under section 29 of this Act at any time upon obtaining significant new scientific information relating to biosafety of the genetically modified organism or contained use activity involved.

[Issue 1] 14 [Rev.

2012] No.

2 of 2009 Biosafety (2) A regulatory agency or an applicant may request the Authority to review its decision with respect to an activity conducted by the applicant where the regulatory agency or the applicant considers that (a) a change in circumstances has occurred that may have a material effect on the outcome of the risk assessment upon which the decision was based; or (b) additional scientific or technical information has become available that may have a material effect on the decision or any conditions, limitations or requirements imposed under a decision.

(3) If upon review the Authority is satisfied that a change is warranted, the Authority shall substitute its earlier approval with another approval which shall take into account the changed circumstances.

(4) The Authority shall make a decision on a review within one hundred days from the date of request for the review and shall state clearly the reasons for its decision.

(5) Where the Authority has knowledge that an activity poses a threat to biosafety, the Authority shall take immediate action to put necessary safety measures in place.

(6) The Authority shall give special consideration for review requests from a regulatory agency.

34.

Offence of withholding information Where a person upon whom approval has been granted withholds information that becomes available to him before and after the approval of his application, and the information could reasonably be expected to change the evaluation of the risk posed by the persons intended activity, such person commits an offence and is liable on conviction to a fine not exceeding two million shillings, or imprisonment for a term not exceeding ten years, or both.

35.

Establishment of the Appeals Board (1) There is hereby established an Appeals Board which shall consist of (a) a chairperson who shall be an advocate of the High Court qualified for appointment as a judge of the High Court of Kenya, appointed by the Minister; (b) four other persons, each of whom shall be an expert in either biological, environmental or social sciences, appointed by the Minister.

(2) Appointments to the Appeals Board shall be by notice in the Gazette.

(3) A member of the Appeals Board shall hold office for three years.

(4) Any person who is aggrieved by (a) a refusal to grant an approval; (b) the imposition of any conditions on an approval; (c) the revocation, suspension or variation of an approval; (d) a refusal to treat an application as confidential; 15 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety (e) a decision of a biosafety inspector; (f) any other decision of the Authority under this Act, may, within thirty days of being notified of the relevant decision of the Authority, appeal to the Appeals Board in the prescribed manner.

(5) Any person aggrieved by a decision of the Appeals Board may, within thirty days of the making of the decision, appeal against the decision to the High Court.

(6) The decision of the High Court on any appeal under this section shall be final.

(7) Subject to subsection (8), the Appeals Board shall regulate its own procedure.

(8) The Minister may make rules (a) prescribing the manner in which an appeal shall be made to the Appeals Board and the fees to be paid in respect of an appeal; (b) prescribing a scale of costs which may be awarded by the Appeals Board; and (c) generally for the better carrying out of the provisions of this Act relating to the Appeals Board and appeals thereto.

(9) The Appeals Board shall communicate its final decision to the appellant within ninety days from the date the appeal was made.

36.

Powers of the Appeals Board (1) On hearing an appeal, the Appeals Board shall have the powers of a court to summon witnesses, take evidence upon oath or affirmation, and to call for the production of books and other documents.

(2) Where the Appeals Board considers it desirable for the purpose of avoiding expense or delay or any other special reason so to do, it may receive evidence by affidavit and administer interrogatories and require the person to whom interrogatories are administered to make a full and true reply to the interrogatories within the time specified by the Appeals Board.

(3) In the determination of any matter, the Appeals Board may take into consideration any evidence which it considers relevant to the subject of an appeal before it, notwithstanding that such evidence would not otherwise be admissible under the law relating to evidence.

(4) The Appeals Board shall have the power to award the costs of any proceedings before it and to direct that costs shall be taxed in accordance with any scale prescribed.

(5) All summonses, notices or other documents issued under the hand of the chairperson of the Appeals Board shall be deemed to be issued by the Appeals Board.

(6) Any interested party may be represented before the Appeals Board by an advocate or by any other person whom the Appeals Board may admit to be heard on behalf of the party.

[Issue 1] 16 [Rev.

2012] No.

2 of 2009 Biosafety 37.

Provisions as to the Appeals Board The provisions of the Sixth Schedule shall apply to the Appeals Board.

PART V REGULATORY AGENCIES 38.

Consultation with regulatory agencies (1) The Authority shall coordinate all activities involving genetically modified organisms and in carrying out its role of coordination, the Authority may consult with the relevant regulatory agency.

(2) Regulatory agencies shall, where appropriate, monitor any activity for which approval has been granted by the Authority to ensure that such an activity complies with conditions imposed, if any, on the grant of an approval.

(3) Where a regulatory agency, in carrying out its mandate, becomes aware of any significant new scientific information indicating that approved activities with genetically modified organisms may pose potential biosafety risks not previously known, the regulatory agency shall immediately inform the Authority of the new information and of the measures proposed to be put in place to ensure the continued safe use of the genetically modified organism.

39.

Unintentional release into the environment (1) A regulatory agency with knowledge of an unintentional or unapproved introduction into the environment of a genetically modified organism that is likely to pose biosafety risks shall, within twenty-four hours of knowledge of the introduction, notify the Authority of the occurrence.

(2) A notification under this section shall include such adequate information as would enable the Authority to mitigate any adverse effects to both human beings and the environment.

(3) The Authority shall, in consultation with the regulatory agency concerned, determine whether any action is necessary to minimize any biosafety risks.

PART VI RESTORATION AND CESSATION ORDERS 40.

Environmental restoration order (1) The Authority may issue and serve on any person a restoration order in respect of any matter relating to release of a genetically modified organism into the environment.

(2) An environmental restoration order issued under subsection (1) shall be issued to (a) require the person on whom it is served to restore the environment as near as it may be to the state in which it was before the release of a genetically modified organism; (b) levy a charge on the person on whom it is served which, in the opinion of the Authority, represents a reasonable estimate of the costs of any action taken by an authorized person or organization to restore the environment to the state in which it was before the release of a genetically modified organism.

17 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety 41.

Contents of restoration order An environmental restoration order shall specify clearly and in a manner which may be easily understood (a) the activity to which it relates; (b) the person to whom it is addressed; (c) the time at which it comes into effect; (d) the action which should be taken to remedy the harm to the environment and the time, being not more that thirty days or such further period as may be prescribed in the order, within which the action should be taken; and (e) the penalty which may be imposed if the action specified is not undertaken.

42.

Cessation orders (1) The Authority, in consultation with the relevant regulatory agency, may issue an order for the immediate cessation of an approved activity, or for the immediate imposition of additional risk management measures with respect to such activity, if the Authority, in consultation with the relevant regulatory agency, determines that there is an imminent danger posed to the conservation and sustainable use of biological diversity, taking into account risks to the human health on the basis of (a) one or more tests conducted and evaluated in a manner consistent with acceptable scientific procedures; (b) other validated scientific evidence.

(2) The Authority may issue a cessation order (a) upon the failure of any person issued with an approval to demonstrate compliance with such approval after a reasonable period of time; or (b) in the event of non-compliance with the provisions of this Act or regulations made thereunder.

(3) A cessation order issued under this Act may be withdrawn once the Authority determines that sufficient information exists to permit the activity concerned to resume, or to resume in the presence of additional risk management measures, without posing a significant risk to human health and the environment.

PART VII INSPECTION AND MONITORING 43.

Appointment of biosafety inspectors The Minister may, on the recommendation of the Authority, and by notice in the Gazette, appoint duly qualified persons whether by name or by title of office, to be biosafety inspectors of the Authority, for such jurisdictional units as may be specified in the notice of appointment.

[Issue 1] 18 [Rev.

2012] No.

2 of 2009 Biosafety 44.

Functions of biosafety inspectors A biosafety inspector shall (a) monitor compliance with this Act and regulations made thereunder; (b) undertake inspections and submit reports thereof to the Authority; (c) perform such other functions as the Authority may deem necessary.

45.

Powers of biosafety inspectors (1) A biosafety inspector may, in the performance of his duties under this Act, at all reasonable times and without a warrant (a) enter any premises, facility, vessel or property which the inspector has reason to believe it is necessary for him to enter in order to ascertain whether the requirements of this Act or any approval under this Act are being complied with, and may take with him any person duly authorized by the Authority; (b) take with him any equipment or material required for any purpose for which the power of entry is being exercised; (c) carry out such tests and inspections, and make such recordings as may be necessary in the circumstances; (d) direct that any part of premises which he has power to enter, or anything in such premises, shall be left undisturbed for so long as is reasonably necessary for the purpose of any test or inspection; (e) take appropriate samples of any organisms, articles or substances found in any premises which he has power to enter for analysis or any other relevant purpose under this Act; (f) in the case of anything found in the premises which he has power to enter, which appears to him to contain genetically modified organisms which pose biosafety risk, cause it to be dismantled or subjected to any process or test but not so as to damage or destroy it, unless it is necessary; (g) require the production of any records which may be required to be kept under this Act.

(2) When exercising his powers under this Act, a biosafety inspector shall suitably identify himself.

PART VIII FINANCIAL PROVISIONS 46.

Funds of the Authority The funds and assets of the Authority shall consist of (a) such moneys as may be appropriated by Parliament for the purposes of the Authority; (b) such moneys or assets as may accrue to or vest in the Authority in the course of the exercise of its powers or the performance of its functions under this Act; (c) such moneys as may be payable to the Authority pursuant to this Act or any other written law; 19 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety (d) such gifts as may be given to the Authority; and (e) all moneys from any other source provided, donated or lent to the Authority.

47.

Annual estimates (1) At least three months before the commencement of each financial year, the Board shall cause to be prepared estimates of the revenue and expenditure of the Authority for that financial year.

(2) The annual estimates shall make provision for all estimated expenditure of the Authority for the financial year concerned, and in particular shall provide for (a) the payment of the salaries, allowances and other charges in respect of the officers, members of staff, or agents of the Authority; (b) the payment of the pensions, gratuities and other charges in respect of retirement benefits payable to the members of staff of the Authority; (c) the proper maintenance of the buildings and grounds of the Authority; (d) the proper maintenance, repair and replacement of the equipment and other movable property of the Authority; and (e) the creation of such reserve funds to meet future or contingent liabilities in respect of retirement benefits, insurance, replacement of buildings or equipment, or in respect of such other matters as the Board may deem fit.

(3) The annual estimates shall be approved by the Board before the commencement of the financial year to which they relate and, once approved, the sum provided in the estimates shall be submitted to the Minister for approval.

(4) No expenditure shall be incurred for the purposes of the Authority except in accordance with the annual estimates approved under subsection (3), or in pursuance of an authorisation of the Board given with prior written approval of the Minister, and the Permanent Secretary to the Treasury.

48.

Accounts and audit (1) The Board shall cause to be kept proper books and other records of accounts of the income, expenditure, assets and liabilities of the Authority.

(2) Within a period of three months after the end of each financial year, the Board shall submit to the Controller and Auditor-General the accounts of the Authority, in respect of that year, together with (a) a statement of income and expenditure during that financial year; and (b) a statement of the assets and liabilities of the Authority on the last day of that financial year.

[Issue 1] 20 [Rev.

2012] No.

2 of 2009 Biosafety (3) The accounts of the Authority shall be examined, audited and reported upon annually by the Controller and Auditor-General in accordance with the provisions of the Public Audit Act (No.

12 of 2003).

49.

Investment of funds The Board may (a) invest any of the funds of the Authority in securities in which the Board may by law invest trust funds, or in any other securities which the Treasury may, from time to time, approve; (b) place on deposit, with such bank or banks as it may determine, any moneys not immediately required for the purposes of the Authority.

PART IX MISCELLANEOUS 50.

Handling, packaging, etc., of genetically modified organisms Any person manufacturing or importing any genetically modified organisms shall ensure that the handling, packaging, identification and transportation of genetically modified organisms is done in the prescribed manner.

51.

Regulations The Minister may, in consultation with the Authority, make regulations for the better carrying into effect the provisions of this Act, and in particular for prescribing (a) anything required by this Act to be prescribed; (b) procedures for conducting contained use activities involving genetically modified organisms; (c) procedures for release of genetically modified organisms into the environment; (d) procedures for importation and exportation of genetically modified organisms; (e) procedures for genetically modified organisms in transit; (f) procedure for handling, packaging, transporting and labelling genetically modified organisms; (g) forms to be used for applications for approvals; (h) schedules of fees to cover administrative costs of processing applications and notices.

52.

Offences and penalties Any person who (a) makes contained use of, releases into the environment, places on the market, imports or exports a genetically modified organism without the approval of the Authority; (b) contravenes any conditions attached to an approval under this Act; (c) fails to furnish any information as required by this Act; 21 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety (d) uses any confidential information for any purpose not authorized under this Act; (e) uses a genetically modified organism in a manner inconsistent with the approval granted by the Authority or for unethical purposes; (f) obstructs or fails to assist the Authority or officers of the Authority in the performance of their duties under this Act; (g) contravenes any of the provisions of this Act, commits an offence and is liable on conviction to a fine not exceeding twenty million shillings, or to imprisonment for a term not exceeding ten years, or both.

53.

Restriction on institution of proceedings No proceedings for an offence under this Act shall be instituted without a prior written consent of the Attorney-General.

54.

Public awareness and participation (1) The Authority shall promote public awareness and education of the public and those conducting the activities subject to the Act, concerning biosafety matters, through the publication of guidance documents and other materials aimed at improving the understanding of biosafety.

(2) The Authority shall give notice in the Gazette of all decisions made regarding applications for approval.

(3) Upon request, the Authority shall, upon payment of the prescribed fee, avail to any person copies of records kept under section 32, including details of any application that do not qualify as confidential information.

(4) Any person may submit written comments on a proposed decision for any application for placing a genetically modified organism on the market, within thirty days from the date the notice is posted.

55.

Transitional provisions (1) Any application for approval to undertake an activity involving genetically modified organisms, which had been made to the National Council for Science and Technology in accordance with the Science and Technology Act (Cap.

250), and which had not been finally determined on the date on which this Act came into force, shall be deemed to be an application for approval made under this Act and shall be dealt with accordingly.

(2) Any approval to undertake an activity involving genetically modified organisms which had been granted by the National Council for Science and Technology in accordance with the Science and Technology Act (Cap.

250), and which was in force on the date on which this Act came into force, shall be deemed to be an approval of the Authority under this Act.

[Issue 1] 22 [Rev.

2012] No.

2 of 2009 Biosafety FIRST SCHEDULE [Section 2.] REGULATORY AGENCIES 1.

Department of Public Health.

Department of Veterinary Services.

Kenya Bureau of Standards.

Kenya Plant Health Inspectorate Services.

Kenya Industrial Property Institute.

Kenya Wildlife Service.

Pest Control Products Board.

National Environment Management Authority.

SECOND SCHEDULE [Section 9.] PROVISIONS AS TO THE CONDUCT OF BUSINESS AND AFFAIRS OF THE BOARD 1.

Committees and co-opted advisors (1) The Board may establish such committees as it may consider appropriate to perform such functions and responsibilities as it shall determine, but all findings of such committees shall be presented to the Board for its consideration and determination.

(2) The Board may, at any time and for any length of time, invite any person to attend any of its deliberations but such person shall not be entitled to vote on any matter at any meeting of the Board.

Meetings of the Board (1) The Board shall meet at least four times in every financial year.

(2) The chairperson shall preside at every meeting of the Board at which he is present, but in his absence, the members shall elect one of their number who shall, with respect to that meeting and the business transacted thereat, have all the powers of a chairperson.

(3) Unless a unanimous decision is reached, a decision on any matter before the Board shall be by a majority of votes of the members present and in the case of an equality of votes, the chairperson shall have a casting as well as a deliberative vote.

Vacation of office (1) A member of the Board, other than an ex-officio member, shall vacate office on any of the following grounds (a) upon the expiry of his appointment; (b) upon his death; 23 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety (c) if he is adjudged bankrupt; (d) if he is sentenced for any offence against any written law to a term of imprisonment of six months or more; (e) if he is convicted of an offence involving fraud, dishonesty or moral turpitude; (f) if he is absent, without permission of the chairperson of the Board, from three successive meetings of the Board of which he has received notice; (g) upon notice in writing of his intention to resign his office; (h) if in the opinion of the Board, he becomes by reason of mental or physical infirmity incapable of performing his duties as a member of the Board; or (i) upon the commission of an offence under this Act.

Disclosure of interest If a member of the Board has any interest direct or indirect in any application or other matter which is the subject of consideration at a meeting of the Board, the member shall, at the meeting, disclose the fact to the Board and shall take no part in the consideration or discussion of or vote on any question with respect to the application or the other matter.

THIRD SCHEDULE [Section 18.] INFORMATION REQUIRED IN APPLICATIONS FOR APPROVAL OF CONTAINED USE ACTIVITY 1.

The name and contact address of the applicant.

The location where contained use activities are to be undertaken.

The nature and identity of genetically modified organisms to be involved.

The nature and purpose of the activities including such activities as storing, transporting, producing, processing, disposing or using the genetically modified organisms in any other way.

A description of the containment measures to be provided and the suitability of those measures for the genetically modified organisms and activities to be undertaken.

A description of any potential risks associated with the genetically modified organisms or the activities to be undertaken, and 7.

A description of remedial measures to be undertaken in the event of any accident.

A sworn declaration by the applicant that the above information is factually correct.

[Issue 1] 24 [Rev.

2012] No.

2 of 2009 Biosafety FOURTH SCHEDULE [Sections 19, 20 and 21.] INFORMATION REQUIRED IN APPLICATIONS FOR APPROVAL OF RELEASE INTO THE ENVIRONMENT, IMPORTATION AND PLACING ON THE MARKET OF GENETICALLY MODIFIED ORGANISMS 1.

Name, address and contact details of the applicant.

Name and identity of the genetically modified organism as well as the domestic classification, if any, of the Biosafety level of the genetically modified organism in the country of export.

Intended dates of the trans-boundary movement.

Taxonomic status, common name, point of collection or acquisition and characteristics of the recipient organism or parental organism related to Biosafety.

Centre of origin and centre of genetic diversity if known, of the recipient organism and the parental organism and the description of the habitat where the organism may persist.

Taxonomic status, common name, point of collection or acquisition and characteristics of the modification introduced, the technique used and the resulting characteristics of the genetically modified organism.

Intended use of the genetically modified organism.

Quantity or volume of the genetically modified organism to be transferred.

Suggested methods for the safe handling, storage, transport and use.

10.

A sworn declaration of the applicant that the above mentioned information is factually correct.

FIFTH SCHEDULE [Section 27.] PROVISIONS ON RISK ASSESSMENT 1.

Objective of risk assessment The objective of the risk assessment is to identify and evaluate the potential adverse effects of genetically modified organisms on human health and the environment.

Use of risk assessment The risk assessment shall be used by the Authority to make informed decisions regarding genetically modified organisms.

25 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety 3.

General principles The general principles guiding risk assessment are (a) risk assessment shall be carried out in a scientifically sound and transparent manner and may take into account expert advice and guiding principles developed by relevant organizations; (b) lack of scientific knowledge or scientific consensus shall not necessarily be interpreted to indicate a particular level of risk, an absence of risk or an acceptable risk; (c) risk associated with genetically modified organisms shall be considered in the context of the risks posed by the genetically modified organisms recipient or the parental organisms in the likely potential receiving environment; 4.

Methodology To fulfil its objective, a risk assessment shall entail the following steps (a) an identification of any genotype and phenotypic characteristics associated with the genetically modified organisms that may have adverse effects on the environment and on human health; (b) an evaluation of the likelihood of these adverse effects being realized, taking into account the level and the kind of exposure of the likely potential receiving environment of the genetically modified organisms; (c) an evaluation of the consequences should these effects be realized; (d) an estimation of the overall risk posed by the genetically modified organisms based on the evaluation of the likelihood and consequences of the identified adverse effects being realized; (e) a recommendation as to whether or not the risks are acceptable or manageable, including identification of strategies to manage these risks; and (f) where there is uncertainty regarding the level of risk, the Authority may request for further information on the specific issues of concern or may recommend implementing appropriate risk management strategies and monitoring the genetically modified organisms in the receiving environment.

Points to consider Risk assessment shall take into account the relevant technical and scientific details regarding the characteristics of the following subjects (a) Recipient organism or parental organism The biological characteristics of the recipient organism or parental organism including taxonomic status, common name, origin, centres of origin and centres of genetic diversity and a description of the habitat where the organism persists.

(b) Donor organism Taxonomic status and common name, source and the relevant biological characteristics of the donor organisms.

[Issue 1] 26 [Rev.

2012] No.

2 of 2009 Biosafety (c) Vector Characteristics of the vector including its identity and the sources of origin and host range.

(d) Insert and characteristics of modification Genetic characteristics of the inserted nucleic acid and the function it specifies and characteristics of the modification introduced.

(e) Genetically modified organisms Identity of the genetically modified organisms and the differences between the biological characteristics of the genetically modified organisms and those of the recipient organism or parental organism.

(f) Detection and identification of genetically modified organisms Suggested detection and identification methods and the specificity, sensitivity and reliability.

(g) Information relating to the intended use Information related to the intended use of the genetically modified organisms including new or changed use compared to the recipient organism or parental organism.

(h) Receiving environment Information on the location, geographical, climatic and ecological characteristics including relevant information on biological diversity and centres of origin of the likely potential receiving environment.

SIXTH SCHEDULE [Section 37.] PROVISIONS AS TO THE APPEALS BOARD 1.

Vacation of office (1) A member of the Appeals Board may vacate office on any of the following grounds (a) upon the expiry of his appointment; (b) upon his death; (c) if he is adjudged bankrupt; (d) if he is sentenced for any offence against any written law to a term of imprisonment of six months or more; (e) if he is convicted of an offence involving fraud, dishonesty or moral turpitude; (f) if he is absent, without permission of the chairperson of the Appeals Board from three successive sittings of the Appeals Board of which he has received notice; (g) upon giving notice in writing of his intention to resign his office; 27 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety (h) if he becomes, by reason of mental or physical infirmity, incapable of performing his duties as a member of the Appeals Board; or (i) upon the commission of an offence under this Act.

Disclosure of interest If a member of the Appeals Board has any interest direct or indirect in any application or other matter which is the subject of consideration at a sitting of the Appeals Board, the member shall at the sitting, disclose the fact to the Appeals Board and shall take no part in the consideration or discussion of or vote on any question with respect to the application or the other matter.

Vacancy Where the office of any member becomes vacant, whether by death or otherwise, the Minister may appoint another person to be a member of the Appeals Board for the remainder of the term of the member whose vacancy caused the appointment.

Majority decisions The decision of the Appeals Board shall be that of the majority and shall be signed by the members thereof agreeing thereto.

Venue The Appeals Board shall sit at such place as it may consider most convenient having regard to all the circumstances of the particular proceedings.

Proof of documents A document purporting to be a copy of any order of the Appeals Board, and certified by the chairperson to be a true copy thereof, shall in any legal proceedings be prima facie evidence of the order.

[Issue 1] 28 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] NO.

2 OF 2009 BIOSAFETY ACT SUBSIDIARY LEGISLATION List of Subsidiary Legislation Page 1.

Biosafety (Contained Use) Regulations, 2011.

31 2.

Biosafety (Import, Export and Transit) Regulations, 2011.

83 3.

Biosafety (Environmental Release) Regulations, 2011.

93 4.

Biosafety (Labelling) Regulations, 2012.

107 29 [Issue 1] [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] BIOSAFETY (CONTAINED USE) REGULATIONS, 2011 ARRANGEMENT OF REGULATIONS PART I PRELIMINARY Regulation 1.

Citation.

Interpretation.

Objective.

Exceptions.

PART II CONTAINMENT MEASURES 5.

Classification of containment levels.

Institutional Biosafety Committee.

Application for contained use.

Consideration of application.

Approval.

10.

Validity of the approved activity.

11.

Suspension or revocation of approval.

12.

Handling of new information.

13.

Contingency plan.

14.

Contents of contingency plans.

15.

Emergency measures.

PART III MISCELLANEOUS 16.

Information sharing and records.

17.

Registration of decisions in the National Biosafety Clearing House.

18.

Confidential information.

19.

Good containment measures.

20.

Handling of modified plasmids and vectors.

21.

Penalties.

SCHEDULES FIRST SCHEDULE TECHNIQUES WHICH DO NOT LEAD TO GENETICALLY MODIFIED ORGANISMS SECOND SCHEDULE CLASSIFICATION OF CONTAINMENT LEVELS THIRD SCHEDULE APPLICATION FORMS FOR CONTAINED USE FOURTH SCHEDULE APPROVAL TO CONDUCT CONTAINED USE ACTIVITY USING GENETICALLY MODIFIED ORGANISMS FIFTH SCHEDULE CONTINGENCY PLAN 31 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] BIOSAFETY (CONTAINED USE) REGULATIONS, 2011 [L.N.

96/2011.] PART I PRELIMINARY 1.

Citation These Regulations may be cited as the Biosafety (Contained Use) Regulations, 2011.

Interpretation In these Regulations unless the context otherwise requires accident means any incident involving a significant and unintended release of genetically modified organisms in the course of their contained use which could present an immediate or delayed hazard to human health and the environment; applicant means a person making an application under these Regulations; Authority means the National Biosafety Authority established under section 5 of the Act; Biosafety Clearing-House means a mechanism for exchange of scientific, technical, environmental, socio-economic and legal information and experience with genetically modified organism; confined field trial means any activity undertaken within a field and which involves genetically modified organisms which are controlled by specific measures to ensure safety for humans and for the environment; contained use means any activity undertaken within a facility, installation or other physical structure, which involves genetically modified organisms which are controlled by specific measures; contained use premises includes a facility, field, installation or other physical structure in which contained use is undertaken; Institutional Biosafety Committee means a committee established under regulation 6 of these Regulations; genetically modified organism means an organism that possesses a novel combination of genetic material obtained through the use of modern biotechnology techniques; modern Biotechnology includes the application of (a) in-vitro nucleic acid techniques including the use of recombinant deoxyribonucleic acid (DNA) and direct injection of nucleic acid into cells or organelles; or (b) fusion of cells beyond the taxonomic family, that overcome natural physiological, reproductive and recombinant barriers and which are not techniques used in traditional breeding and selection.

regulatory agency means a regulatory agency as set out in the First Schedule to the Act, or such other agency as the Minister may, by Order in the Gazette, determine.

[Issue 1] 32 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] research institution includes a university, or any other research institution registered in Kenya or established under a written law, carrying out research involving genetically modified organisms; screening for completeness means the evaluation of an application to ensure that all the administrative as well as technical requirements are met.

Objective The objective of these Regulations is to ensure that potential adverse effects of genetically modified organisms are addressed to protect human health and the environment when conducting contained use.

Exceptions These Regulations shall not apply (a) to genetically modified organisms which are pharmaceuticals for human use; (b) where genetic modification is obtained through the use of the techniques or methods listed in the First Schedule; (c) to the storage, culture, transport, destruction, disposal or use of genetically modified organisms which have been released into the environment in accordance with the Biosafety (Environmental Release) Regulations, 2011.

PART II CONTAINMENT MEASURES 5.

Classification of containment levels (1) The Authority shall ensure that all appropriate measures are taken to avoid adverse effects on human health and the environment, which might arise from the contained use of a genetically modified organism.

(2) The Authority in consultation with the relevant regulatory agency shall assess the suitability of a contained use premises to conduct contained use activity involving genetically modified organism.

(3) Upon carrying out the assessment, the Authority in consultation with the relevant regulatory agency shall determine the containment level of the contained use premises in accordance with the provisions of the Second Schedule.

(4) The containment levels under this Regulation apply to laboratory, greenhouse or screen house activities.

(5) Appropriate measures for confined field trials shall be determined through procedures developed by the Authority in consultation with the relevant Regulatory Agency.

Institutional Biosafety Committee (1) A research institution undertaking contained use activities shall establish an Institutional Biosafety Committee.

(2) An Institutional Biosafety Committee shall consist of (a) biosafety officer(s); (b) scientist(s) in the relevant field; (c) representative(s) of technical staff; (d) representative(s) of laboratory management; 33 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] (e) representative(s) of the community where the premises are situated; and (f) representative(s) of the relevant regulatory agency.

(3) The functions of an Institutional Biosafety Committee shall be (a) to prepare applications for contained use activities and refer the applications to the Authority for approval; (b) to advise the research institution on matters relating to biosafety; (c) to assist the institution in the establishment of the appropriate monitoring mechanisms for risk assessments and risk management; (d) to ensure compliance with the conditions set out in the approval; (e) to review and ascertain the suitability of both physical and biological containment and control procedures appropriate to the level of assessed risk involved in research, development and application activities; (f) to advice the institution and principal investigators on mitigation measures to be undertaken in case of an accident.

(4) A person shall not carry out contained use activity under these Regulations unless such activity is carried out within, or in collaboration with, a research institution.

(5) A person who contravenes sub regulation (4) commits an offence.

Application for contained use (1) A person shall not undertake contained use without the written approval of the Authority.

(2) An application for contained use shall be made to the Authority through an Institutional Biosafety Committee.

(3) An application for contained use shall be in the form set out in the Third Schedule to these Regulations and shall be accompanied by an application fee of one hundred and seventy thousand shillings.

(4) A person who contravenes sub regulation (1) commits an offence.

Consideration of application (1) Upon receipt of an application under regulation 7, the Authority shall screen for completeness and circulate the application to the relevant regulatory agencies for further information, comments or reasoned objections.

(2) The Authority shall examine the application to confirm (a) that the application conforms with the requirements of these Regulations; (b) the accuracy and completeness of the information given; (c) the risk assessment submitted by the applicant; (d) the level of contained uses; and (e) where appropriate, the suitability of the containment and other protective measures, the waste management, and contingency measures.

(3) The Authority may (a) require the applicant to provide further information; or (b) require the applicant to modify the conditions of the proposed contained use, or to amend the level assigned to the contained use; or (c) limit the time for which the contained use should be permitted or subject it to certain specific conditions.

[Issue 1] 34 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] (4) The Authority shall communicate its final decision within one hundred and fifty days of receipt of the application but not earlier than ninety days of such receipt.

(5) For the purpose of calculating time, any period of time during which the Authority is awaiting any further information that it may have requested from the applicant shall not be taken into account.

Approval (1) An approval for contained use shall be in the form set out in the Fourth Schedule.

(2) An approval granted under these Regulations shall be valid for the period of the activity in respect of which it is granted.

(3) An approval for contained use is not transferable.

10.

Validity of the approved activity (1) An approval under these Regulations shall be for the period of the activity.

(2) A grantee under these Regulations shall submit quarterly reports on the progress of the activity during the period of the approved activity.

11.

Suspension or revocation of approval (1) The Authority may suspend or revoke an approval granted under these Regulations, where the grantee is in contravention of the provisions of these Regulations.

(2) The Authority shall, before suspending or revoking an approval, give a written notice to the grantee to put in place such appropriate containment measures or other protective measures.

12.

Handling of new information (1) A grantee who subsequently becomes aware of information which could have significant consequences for the risks posed by it, shall inform the Authority of such information as soon as possible.

(2) A person who withholds any information that becomes available before and after the approval of the application, and which could reasonably be expected to change the evaluation of the risk posed by the activity, commits an offence and is liable on conviction to a fine not exceeding two million shillings or imprisonment for a term not exceeding ten years, or both.

(3) Where information which could have significant consequences for the risks posed by the contained use, subsequently becomes available, the Authority may require the grantee to modify the conditions of, or suspend or terminate, the contained use.

(4) A grantee, who wishes to request for an extension or to modify the contained use, may make a written request to the Authority and the Authority shall within thirty days acknowledge receipt of the request.

(5) The Authority shall review the request and where it considers that the proposed extension or modification (a) does not require risk assessment, the Authority shall communicate its decision within thirty days from the date of the receipt of the request; or (b) may have material effect on the outcome of the risk assessment upon which the decision was based, the Authority shall, if is satisfied that a change is warranted, make a decision within one hundred days from the date of the receipt of the request.

35 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] 13.

Contingency plans The Authority shall ensure that before contained use commences (a) the applicant draws up a contingency plan for contained use to mitigate against risk, whether immediate or delayed, to humans outside the premises or to the environment as a result of failure of the contained use measures; (b) Information on such contingency plans, including the relevant safety measures to be applied, is supplied, to the relevant regulatory agency for purposes of monitoring for compliance.

14.

Contents of contingency plans Every contingency plan shall be in the form set out in the Fifth Schedule.

15.

Emergency measures (1) In the event of an accident, a grantee shall inform the Authority immediately and shall provide the following information (a) the circumstances and location of the accident; (b) the identity and quantities of the genetically modified organisms; (c) any information necessary to assess the effects of the accident on human beings, and the environment; and (d) the measures taken to mitigate against risk.

(2) Where information is given pursuant to sub regulation (1), the Authority shall (a) ensure that necessary measures are taken to control the effects of the accident; (b) where possible, collect, information necessary for a full analysis of the accident; and (c) where appropriate, make recommendations on how to avoid a similar accident in the future and to limit the effects thereof.

(3) A person who contravenes sub regulation (1) commits an offence.

PART III MISCELLANEOUS 16.

Information sharing and records (1) The Authority shall maintain a register which shall contain (a) a copy of the (i) application; (ii) risk assessment document; (iii) decision document; (iv) approval document; and (v) contingency plan; (b) a list of institutional biosafety committees; and (c) any other information that the Authority may deem necessary.

(2) The register shall be open for inspection by any interested person upon payment of an inspection fee of five hundred shillings.

(3) The Authority shall establish a procedure for the exchange of information and experiences gained.

[Issue 1] 36 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] 17.

Registration of decisions in the National Biosafety Clearing House The Authority shall register all decisions made under these Regulations in the National Biosafety Clearing House within thirty days of making the decision.

18.

Confidential information (1) An applicant may request that certain information in his application be treated as confidential and shall give reasons for the request.

(2) The Authority shall determine if the information should be kept confidential and shall communicate its decision to the applicant in writing.

(3) The following information shall not be considered confidential (a) name and address of the applicant; (b) the general characteristics of the genetically modified organism; (c) class of contained use and measures of containment; and (d) the evaluation of foreseeable effects, in particular any harmful effects on human health and the environment.

(4) The authority shall protect the intellectual property rights of the applicant.

(5) Where an applicant withdraws an application, the Authority shall maintain confidentiality on the information supplied.

19.

Good containment measures An applicant shall apply the general principles and the appropriate containment and other protective measures set out in Part II of the Second Schedule to these Regulations corresponding to the class of the contained use.

20.

Handling of modified plasmids and vectors Modified plasmids or vectors used as tools for modern biotechnology shall be approved by the relevant regulatory agency.

21.

Penalties A person who contravenes any of the provisions of these Regulations commits an offence and is liable on conviction to a fine not exceeding twenty million shillings or to imprisonment for a term not exceeding ten years, or both.

FIRST SCHEDULE [Rule 4.] TECHNIQUES WHICH DO NOT LEAD TO GENETICALLY MODIFIED ORGANISMS The following technical procedures shall not be considered to amount to formation of genetically modified organisms without concurrent use of recombinant heritable genetic material (a) in vitro fertilization; (b) bacterial conjugation, transformation, transduction and similar natural processes; (c) polyploidy and haploidy induction; (d) Mutagenesis.

37 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] SECOND SCHEDULE [Rule 5(3).] PART I CLASSIFICATION OF CONTAINMENT LEVEL Level 1 Activities with no or negligible risk of adverse effect on human health, the environment and biological diversity.

Level 2 Activities with low risk of adverse effect on human health, the environment and biological diversity that can easily be eliminated using generally known procedures for which the level of containment and protective measures are laid down.

Level 3 Activities with a moderate risk of such adverse effect on human health, the environment and biological diversity that can only be eliminated by especially demanding interventions for which the level of containment and protective measures are laid down.

Level 4 Activities with high risk of adverse effect on human health, the environment and biological diversity for which the level of containment and protective measures are laid down.

PART II [Rule 19.] GENERAL REQUIREMENTS FOR GOOD CONTAINMENT MEASURES A: Checklist for Inspection Animal Units Containment level Specification 12341 Isolation of animal unit optional yes yes yes 2 Animal facilities separated by lockable doors optional yes yes yes 3 Animal facilities designed to facilitate optional optional yes yes decontamination (waterproof and easily washable material, cages etc.) 4 Floor and/or walls easily washable optional floor floor and floor and walls walls 5 Floor to wall, wall to ceiling and wall to wall yes yes yes yes junctions should be rounded for easy cleaning 6 All joints between door frames and wall should yes yes yes yes be sealed 7 Animal facilities have to be cleaned regularly.

no yes yes yes Sinks have to be disinfected regularly.

8 Surfaces have to be disinfected after work no yes yes yes 9 Used cages have to be decontaminated yes yes yes yes 10 Material to be sterilised or incinerated as well yes yes yes yes as used cages have to be transported so that the environment is not contaminated 11 Hands have to be decontaminated and yes yes yes yes washed if there is the possibility of contamination and after handling animals and waste [Issue 1] 38 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] SECOND SCHEDULEcontinued Containment level Specification 1234 12 Access to animal facilities is restricted yes yes yes yes 13 An animal unit shall have installed devices to yes yes yes yes detect fires, ventilation and heating failures and the intrusion of unauthorised personnel 14 Where appropriate, an inspection window yes yes yes yes should be fitted in the door 15 Animal facilities have to be aerated yes yes yes yes appropriately 16 Wild forms of the animals inside the facility yes yes yes yes should not be able to enter the facility.

Separate male and female of the species to avoid reproductive transmission, unless reproductive studies are part of the experiment 17 Measures to control undesired species such yes yes yes yes as insects and rodents 18 Drains and any other services that enter yes yes yes yes through the walls or floor should prevent the ingress of rodents and insects 19 Accidents, bites and scratches caused by yes yes yes yes animals have to be reported to the project leader who makes a written report 20 Personnel has to be trained in the handling of yes yes yes yes the animals 21 There have to be written records about the yes yes yes yes transfer of foreign genes, about the breeding experiments and the disposal of animals 22 Transgenic animals have to be identified yes yes yes yes easily.

The insert can serve as an additional marker 23 Food and tobacco has to be stored so that it yes yes yes yes cannot come in contact with transgenic animals 24 Protective clothing and shoes have to be yes yes yes yes worn.

They have to be changed or cleaned when the facility is left.

25 Protective clothing has to be stored separated no yes yes yes 26 Rodentbarrier in front of doors should be yes yes yes yes installed, alternative doors should be self- closing, to rooms where animals are housed and handled to prevent the escape of animals 27 Animal species shall be housed in appropriate yes yes yes yes cages, runs, pens suitable for their requirements 39 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] SECOND SCHEDULEcontinued Containment level Specification 1234 28 No animals should be admitted other than for yes yes yes yes experimental purposes 29 Biohazard sign no yes yes yes 30 Doors have to be closed if infected animals no yes yes yes are held.

There must be a sign indicating the kind of work 31 The laboratory should contain a washbasin no yes yes yes with taps that should be of a type that can be operated without being touched by hand, facilities for hand disinfecting shall be provided 32 Use of safety cabinets where aerosols are no yes yes yes released 33 An autoclave should be available when yes yes yes yes genetically modified micro-organisms are used in experiments 34 In experiments where genetically modified yes yes yes yes micro-organisms are used contaminated material and waste should be inactivated 35 If genetically modified organisms can be no yes yes yes transmitted, working tools and equipment have to be sterilised 36 Waste contaminated with genetically modified no yes yes yes organisms must only be transported in suitable containers 37 Genetically modified organisms must only be no yes yes yes transported in breakproofed and closed containers 38 Where risk assessment indicates the animal no yes yes yes room and contents will need to be fumigated the room should be capable of being sealed by appropriate means and consideration should be given to the means of removing or extracting the fumigant 39 Hygiene plan no yes yes yes 40 The animal facility has to be entered via a lock no no yes yes equipped with two self closing doors, hand washing basin, disinfection dispenser and shower 41 Acceptability of windows that open yes yes no no 42 Emergency power supply for safety relevant no no yes yes equipment such as ventilation system 43 Where mechanical ventilation is provided, the no yes yes yes airflow should be inwards.

Air should not be recirculated to any part of the building.

[Issue 1] 40 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] SECOND SCHEDULEcontinued Containment level Specification 1234 44 The ventilation system should be designed to no no yes yes prevent accidental reverse flow and positive pressurisation in any part of the animal unit 45 In case of work with airborne pathogens no no yes yes negative pressure relative to the pressure of the immediate surroundings, extract air should be HEPA* filtered 46 HEPA* filters should be sited so that they are no no yes yes accessible for testing and allow their safe removal.

HEPA filters have to be sterilised on site or immediately sealed in an airtight plastic sack for later sterilisation 47 Animals infected with risk group 3 micro- no no yes yes organisms shall be housed in cages in isolators with ventilation passing through HEPA* filtration to the exterior.

Alternatively, animals shall be housed in cages within ventilation units with ventilation exhausts placed behind cages.

48 Carcasses have to be sterilised prior to no no yes yes disposal.

If this is not possible inside the facility, carcasses have to be trans-ported in closed, leakproofed and disinfected containers 49 Waste water has to be sterilised no no yes yes * High-efficiency particle arresting B: Checklist for Inspections (Contained Use Glasshouses and Growth-Rooms) Containment level Specification 12341 Greenhouse: permanent structure no yes yes yes 2 Internal walls, ceilings and floors no optional yes yes shall be resistant to penetration by liquids and chemicals to facilitate cleaning and decontamination of the area.

All penetrations into these structures and surfaces shall be sealed (e.g.

cables, pipes) 3 Control of contaminated run-off optional minimise prevent prevent water run-off run-off run-off 4 There must be a suitable program to yes yes yes yes control plant pests, weeds, insects and rodents 41 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] SECOND SCHEDULEcontinued Containment level Specification 12345 Measures to control yes yes yes yes undesired species such as weed, insects, rodents, arthropods 6 Procedures for transfer of minimise minimise prevent prevent living material between the dissemination dissemination dissemination dissemination glasshouse/growth-room, protective structure and laboratory shall control dissemination of genetically modified micro-organisms 7 Transport of GMOs in no yes yes yes suitable closed non- breakable container 8 The container shall be no no yes yes decontaminated if organisms outside are present within the effective dissemination distance of the experimental organism, e.g.

by fumigation 9 The ground of the yes yes yes yes greenhouse can be of gravel or other greenhouse-typical material.

At least the pavement should be solid, e.g.

of concrete.

10 The ground of the no yes not not greenhouse should be of applicable applicable water impermeable material.

Gravel and other porous material under the planting tables are suitable if there is only a minor possibility that reproducible biological material can be transmitted through the soil.

In this case earth beds are also possible.

11 If part of the ground consists no yes not not of gravel, appropriate applicable applicable treatments should be made periodically to eliminate, or render inactive, any organisms potentially entrapped by the gravel 12 The ground of the no no yes yes greenhouse is made of water impermeable material with provisions to collect and sterilise wastewater.

13 Escape of GMOs minimised prevent prevent prevent [Issue 1] 42 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] SECOND SCHEDULEcontinued Containment level Specification 1234 14 Windows shall be closed no no yes yes and sealed with insect nets 15 All glazing shall be resistant no no yes yes to breakage 16 Biohazard sign at entry no yes yes yes 17 A sign shall be posted no optional yes yes indicating - That a restricted experiment is in progress - Name of responsible individual - Plants (organisms) in use - Special requirements for using the area 18 Access is limited to the no yes yes yes project leader and personnel authorised by him 19 Protective clothing shall not yes yes yes yes be worn outside the greenhouse 20 Separate facilities for storing no yes yes yes protective and street clothing shall be available 21 Protective clothing has to be no no yes yes sterilised before laundry 22 Gloves shall be worn at no no yes yes work 23 Injuries have to be reported yes yes yes yes immediately to the project leader 24 There must be written yes yes yes yes instructions for greenhouse practices and procedures 25 Hand disinfection apparatus no yes yes yes and wash basin 26 Greenhouse to be entered no no yes yes via a lock with self-closing doors and hand disinfection apparatus and touch-free hand washing basin.

27 Air intake screening and yes yes not not motorised or gravity-driven applicable applicable exhaust fan louvers 43 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] SECOND SCHEDULEcontinued Containment level Specification 1234 28 The glasshouse has to be no no yes yes held under negative pressure compared to the surrounding 29 If there is the danger of the no no yes yes dissemination of airborne pathogens, exhaust air has to be filtered through HEPA*filters 30 Before disposal genetically yes not not not modified plants have to be applicable applicable applicable made unable to reproduce, e.g.

by cutting off blossoms 31 Equipment which was in no yes yes yes contact with GMOs has to be sterilised before cleaning, if the contact may lead to the transmission of GMOs 32 Autoclave inside the no no, but yes yes glasshouse available 33 The glasshouse has to be no no yes yes surrounded by a security fence or equal protection system * High-efficiency particle arresting C: Checklist for Inspections (Contained Use Laboratory Activities) I.

Physical Control Measures (a) Facility design Containment level Specification 12341.

Process with viable micro-organisms separated yes yes yes yes from the environment (closed system) 2.

Laboratory suite isolation no no yes yes 3.

Restricted access to the facility (e.g.

electronic no yes yes yes cards, camera) 4.

laboratory sealable for fumigation no no yes yes 5.

Acceptability of windows that open yes yes no no 6.

Biohazard sign on the door no yes yes yes 7.

Signs at laboratory entrance no yes yes yes - special hazard signs if an organism containing rDNA needs special provision for persons entering the laboratory - names of occupants who have access to the laboratory 8 Ventilation system no no yes yes [Issue 1] 44 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] SECOND SCHEDULEcontinued (b) Containment equipment Containment level Specification 12341 Surfaces resistant to water, acids, alkalis, yes yes yes yes solvents, disinfectants, decontamination agents and easy to clean 2 Suitable of equipment used for safety purposes no yes yes yes 3 Suitable chemical disinfectants in use optional yes yes yes 4 Suitable position of the autoclave with respect on site in the in suite in lab, to the genetically modified organism building double installation closed 5 Autoclave provides a print-out showing the no no yes yes temperature and time of sterilisation 6 Wash hand basin or sink that can be used for yes yes yes yes hand washing with - dispenser containing soap - dispenser containing hand disinfectant - paper towels 7 Appropriate position and design of biological optional yes yes yes safety hoods 8 Suitable design of the equipment for the safe yes yes yes yes storage of genetically modified organisms 9.

Suitable design of waste transport containers optional yes yes yes 10.

Suitable design of containers for the transport optional yes yes yes of genetically modified organisms inside the facility 11.

Suitable design of centrifuge buckets yes yes yes Yes 12.

Entry to lab via airlock no no optional yes 13.

Air lock with two doors which are interlocked no no yes yes 14.

Air lock equipped with a hand washing basin no no yes yes (touch free) and hand disinfectant dispenser 15.

Negative pressure relative to the pressure of no no optional yes the immediate surroundings 16.

Ventilation system is alarmed to indicate a no no yes yes failure to generate a negative pressure 17.

Ventilation system connected to an emergency no no yes yes power supply 18.

Switch for ventilation system should be no no yes yes accessible from outside of the laboratory in case of fumigation 19.

Extract and input air from the laboratory should no no extract air input and be HEPA* filtered extract air 45 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] SECOND SCHEDULEcontinued Containment level Specification 1234 20.

Filters have to be sterilised on site or instantly no yes yes yes sealed in a plastic bag for later sterilisation 21.

Alarm systems for workers working alone no no yes yes 22.

Shower for the occupants before leaving the no no optional yes laboratory 23.

An observation window or alternative is to be optional optional optional yes present so that occupants can be seen * High-efficiency particle arresting II.

Safety Management (a) Work procedures Containment level Specification 12341 Engineering control measures have to be yes yes yes yes exercised at source and supplement these with appropriate personal protective clothing and equipment where necessary 2 Control measures and equipment have to be yes yes yes yes tested adequately and maintained 3 Doors and windows closed while working only doors yes yes yes 4 Access to the laboratory must be restricted no yes yes yes when experiments are in progress 5 Workers should be given adequate information yes yes yes yes on safety matters and be suitably trained.

Training should include the following points (a) the existence and application of written work procedures (b) the procedures for using particular pieces of equipment (c) spillage control and other emergency procedures 6 Check at which process steps hazardous optional yes yes yes quantities of aerosols are formed 7 Prevention of aerosol formation yes yes yes yes 8 Genetically modified organisms are only to be yes yes yes yes transported within the facility in closed, robust and leakproof containers 9 Work surfaces must be decontaminated daily yes yes yes yes and after a spillage 10 Effective disinfectants and specified yes yes yes yes disinfection procedures in case of spillage of genetically modified organisms 11 Inactivation of genetically modified organisms optional yes yes yes in contaminated material and waste [Issue 1] 46 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] SECOND SCHEDULEcontinued Containment level Specification 1234 12 Inactivation of genetically modified organisms no no optional yes in effluent from the hand washing sinks or drains and showers and similar effluents 13 Benches should be free from clutter yes yes yes yes 14 The identity of genetically modified organisms optional yes yes yes should be regularly checked to avoid the culturing of incorrect stains.

(The time between these checks should be dependent upon the potential hazard).

15 Corrective actions following the results of the yes yes yes yes controls and way to register them 16 Users should ensure that the performance of yes yes yes yes safety equipment is validated (e.g.

autoclaves and safety hoods) - validation of equipment (e.g.

autoclaves, safety hoods) - maintenance of the equipment - markers used to verify the efficiency of autoclaves 17 Prohibition of mouth pipetting yes yes yes yes 18 Prohibition of eating, drinking, smoking, yes yes yes yes applying cosmetics or the storing of food for human consumption in the work area 19 Skin contact with rDNA material must be yes yes yes yes avoided 20 Hands must be washed after handling rDNA yes yes yes yes and before leaving the laboratory 21 Protective clothing yes yes yes and yes, optional complete footwear change of clothing & footwear 22 Decontaminate protective clothing before yes yes yes yes laundering 23 Protective clothing and street wear must be yes yes yes yes kept separate 24 Gloves no optional yes yes 25 Implementation of an insect and rodent control optional yes yes yes programme 26 Keep the workplace and environmental yes yes yes yes exposure to any physical, chemical or biological agent to the lowest practicable level 47 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] SECOND SCHEDULEcontinued Containment level Specification 1234 27 Tests, when necessary, for the presence of yes yes yes yes viable genetically modified organisms outside the primary physical containment 28 Use of sharps should be avoided yes yes yes yes 29 Contaminated syringes/sharps must be yes yes yes yes disposed of in a Sharps bin and incinerated 30 Where appropriate make vaccines available no yes yes yes 31 Establish Institutional Biosafety Committees or yes yes yes yes sub-committees as required 32 Animals must not be allowed to enter into the yes yes yes yes laboratory 33 Where appropriate serum samples must be no optional optional optional taken from workers and stored to provide baseline information in the event of an unexplained illness 34 Sample collection, addition of materials to yes yes yes yes closed system and transfer of viable micro- organisms to another closed system, should be performed appropriate 35 Safe storage of biological agents yes yes yes yes 36 Safe storage of contaminated laboratory yes yes yes yes equipment and materials, when appropriate (b) Institutional matters and documentation relating to the safe handling of genetically modified organisms Containment level Specification 12341 Keep adequate records yes yes yes yes 2 Hygiene plan no yes yes yes 3 Provide written standard operating procedures yes yes yes yes where appropriate to ensure safety 4 Provide documentation of the appointment of yes yes yes yes the BioSafety Officer (BSO) 5 The appointment of project leader yes yes yes yes 6A description of the tasks of the BioSafety yes yes yes yes Officer (BSO) with respect to safety; internal control; accident/incident; response and preparedness; internal counselling, advice and education; and, reporting 7A description of the tasks of the project leader yes yes yes yes with respect to - everyday management - drawing-up and executing work-protocol [Issue 1] 48 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] SECOND SCHEDULEcontinued Containment level Specification 12348A clear description of the separation of yes yes yes yes responsibilities and tasks between the BioSafety Officer and the project leader 9 The status of the Biosafety Officer should be yes yes yes yes defined 10 There should be written procedures that cover yes yes yes yes the following - undertaking risk assessments - the training of new staff - emergency procedures including the treatment of spillages with disinfectants - cleaning and disinfection of equipment - transport of GMOs - operation, testing and maintenance of containment equipment - measures for limiting access to facilities - health surveillance of workers 11 Written instructions should be in both national yes yes yes yes languages 12 Documents that should be centrally held within yes yes yes yes an institution undertaking contained use (a) records indicating working areas and their containment levels (these records may include plans of buildings) (b) all of the documents listed in point 10 above (c) these records should also cover any sites for storage Genetically modified organisms outside of containment facilities (d) records of internally organised inspections (e) records of accidents, including evaluation and any remedial action (f) a list of other data and documents that are held at other locations within the institution 13 Documents that can be held separately from the yes yes yes yes main records (see 12 above) (a) records of staff involved in contained use indicating their experience and training and the type of projects in which they have been employed (b) results of procedures for checking the purity and identity of the genetically modified organisms 49 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] SECOND SCHEDULEcontinued Containment level Specification 1234 (c) results of the testing of containment yes yes yes yes equipment (e.g.

autoclaves and safety cabinets) (d) a list of stored genetically modified organisms for each storage facility (e) work protocols for particular experimental procedures NB: Risk assessment of the genetically modified organisms that will be handled in every facility will be evaluation during application to the Authority.

III Contingency Plan Containment level Specification 12341 Check contingency plans for protection of the no no optional yes environment and the public outside of the facility 2 Check information on accidents (reporting of yes yes yes yes accidents and nearmisses and records of corrective actions that have been taken) 3 Provide written procedures for no yes yes yes - a procedure for internal notification of incidents (e.g.

spillages) - a procedure for external notification in case of serious risk - a procedure accident response (measures, reporting, evaluation) - emergency preparedness actions and counter-measures in case of accidents or incidents THIRD SCHEDULE [Rule 7(3).] This Schedule comprises of application forms for contained use activities.

The forms are as follows.

Laboratories, Green houses and Growth chambers.

Confined field trials for Animals, animal health inputs and microorganisms.

Confined field trials for plants.

[Issue 1] 50 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULEcontinued PART I APPLICATION FORM FOR CONTAINED USE ACTIVITY (LABORATORY, GREENHOUSE AND GROWTH CHAMBERS) GENERAL REQUIREMENTS FOR THE APPLICATIONS This application form must be completed for each individual genetically modified organism for the intended contained use activity.

The application may include more than one experiment (genetic modification of that particular species) or protocols and all sections must be completed.

Additional pages can be attached if the space provided is not sufficient.

Applications for new and renewal of previously authorized contained use should be submitted separately.

1.0 Name and Contact Address of Applicant 1.1 Date of Submission 1.2 Name of applicant 1.

3 Name of Institutional Biosafety Committee (IBC) 1.4 Institution of applicant 1.5 Registration Status in Kenya 1.6 Affiliating institution (if institution of applicant is not registered in Kenya) 1.4.1 Address of applicants institution 1.6.1 Address of affiliating institution 1.4.2 Telephone 1.4.3 Facsimile /email 1.6.2 Telephone 1.6.3 Facsimile/email 2.0 Nature and purpose of contained use 2.1 Brief Description of Proposed contained use activity 2.2 Purpose of contained use - character of the activity that will be carried out by applicant (e.g.

research, laboratory control, manufacture) 2.3 If the contained use work is successful, indicate whether a general release of the GMO is planned 2.4 Total period of contained use and date of its expected starting-up 3.0 Risk assessment 3.1 Summary of the risk assessment for the genes and species of GMO involved 51 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] THIRD SCHEDULEcontinued 3.2 Description of potential risks associated with the transformed organism, transformation genes or gene elements.

3.3 Description of potential risks associated with the activities to be undertaken 4.

0 Location where contained use activities are to be undertaken 4.1 Contained Use Facility: Laboratory and growth chambers 4.1.1 Facility Location 4.1.2 Approval No.

or 4.1.3 Number of other contained use reference activities currently approved within the same facility 4.1.4 Biosafety level assigned to facility during approval (Level1, or level 2, or level 3 or level 4) 4.1.5 Layout of premises and of the location of main facilities (Attach additional annex if more space is required) 4.1.6 Code of practice of a workplace (Indicate type) 4.1.7 Emergency Response Plan in the event of an accident 4.1.8 Characteristics of the workplace (Tick as appropriate) 4.1.8.1 Microbiological laboratory 4.1.8.2 Pilot plant 4.1.8.3 Production facilities 4.1.8.4 Glasshouse/growth room 4.1.8.5 Animal breeding facility 4.1.8.6 Other (Specify) 4.1.9 Species and amount of used organism and the used genetic modifications including nominally mentioned validated methods for detection of occurrence of genetically modified organisms 4.1.10 Waste management plan 4.2 Contained Use Facility: Greenhouse Facility 4.2.1 Facility Location 4.2.2 Approval No.

or reference.

4.2.3 Number of other activities currently approved within the same facility.

[Issue 1] 52 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULEcontinued 4.2.4 Protocol: Fully describe the following 4.2.4.1 Purpose of the greenhouse trial 4.2.4.2 Experimental design 4.2.4.3 Nature and type of data to be collected 4.2.5 Arrangements for transporting the GMO to the greenhouse 4.2.6 Proposed herbicide/pesticide use, if any 4.2.6.1 Name of the 4.2.6.2 Active 4.2.6.3 Total area to be sprayed 2 pesticide/herbicide ingredient (m /hectarage) 4.2.7 Provide work schedule (post approval) of key activities including but not limited to: 4.2.7.1 Dates of movement of 4.2.7.2 Planting 4.2.7.3 Harvest/Sampling material (anticipated) (anticipated) 4.2.8 Describe your plan for recording the quantities of seed planted/GMO used and accounting for any excess 4.2.9 Describe the disposition plan, including how and where any excess, or non-planted seed/GMO will be disposed of or stored 4.2.10 State whether plants will be allowed to set seed or to reproduce Yes No 4.2.11 Indicate whether any harvested plant 4.2.11.1 If yes, Type (e.g.

seed, leaves, etc.) material will be retained from the trial Yes No 4.2.11.2 Quantity to be retained 4.2.11.3 Purpose of retaining material 4.2.12 For harvested plant material, describe the following if applicable: 4.2.12.1 The storage method.

4.2.12.2 Storage location 53 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] THIRD SCHEDULEcontinued 4.2.12.3 Person in the institution responsible for the storage of the material 4.2.12.3.1 Name 4.2.12.3.2 Telephone 4.2.12.4 Proposed storage records 5.0.

Nature and identity of Genetically modified organism 5.1 Name of GMO 5.2 Modified trait(s) Identification Herbicide Tolerance Modified Oil Composition Pharmaceutical Male sterility/restoration Virus Resistance Genetic Research Insect Resistance Stress Tolerance Generation of mutants Nutritional change Fungal Resistance Other (Specify) 5.3 Modified Trait(s) Describe each specific new trait associated with this GMO 5.4 For each gene construct, describe all genes, regulatory elements, gene products, non- translated DNA sequences and, where applicable, affected metabolic pathways 5.5 Provide Information on the donor organism including its origin 5.6 Provide Information on recipient and parental organism including origin 5.7 Provide Information on the vector including its origin 5.8 Provide the name of plasmid (construct) and genetic map (map of each genetic construct is required).

5.9 Describe Mode of action of traits (gene product, metabolic pathways).

5.9.1 Is the vector naturally 5.9.2 Is the vector 5.9.3 If yes, how was the pathogenic? disarmed? vector disarmed? Yes No Yes No 5.10 Description of elements of the constructs(s): This area should be filled for all constructs and GMO gene elements [Issue 1] 54 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULEcontinued 5.10.1 Genetic Element 5.10.2 Size (bp) 5.10.3 Source 5.10.4 Function 5.11 Method of introduction of the insert 5.12 Method for detection of genetically modified organism 5.13 Amount of genetically modified organism to be used (volume of the culture, number of plants or animals) 5.14 Information on whether the genetically modified organism has already been approved in some other country and for what purpose 6.0 Nature and purpose of the contained use activities 6.1 In case of import or export of the genetically modified organism intended for contained use 6.1.1 The country of origin or destination, as appropriate 6.1.2 Importer or exporter, as appropriate 6.1.3 Maximum amount of genetically modified organism 6.1.4 Means of transportation to be imported or exported 6.1.5 Means of packaging and labeling 6.2 Measures to protect human health and the environment and biological diversity 6.3 Frequency and the manner of carrying out control of the occurrence of genetically modified organism inside and outside of the contained space 6.4 Description of waste management plan 7.0 Containment measures 7.1 List all protocols proposed to be used at this facility for this application (Separate sheets may be annexed) 7.2 Attach inspection report if facility is not yet assigned a biosafety level 55 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] THIRD SCHEDULEcontinued 7.3 State proposed documentation procedures on the use of genetically modified organisms 7.4 Plan of training of employees prior to the commencement of the use of genetically modified organisms, and the plan of their refresher training 8.0 Declaration of correctness of information I certify that the above information is true to the best of my knowledge.

Principal Investigator Name.

Signature.

Date.

Collaborator(s) Name(s).

Signature.

Date.

Collaborator(s) Name(s).

Signature.

Date.

Institutional Biosafety Committee (IBC) Review This application has been reviewed by IBC Name of IBC.

Name of chairperson.

Signature.

Date.

PART II APPLICATION FORM FOR CONTAINED USE AND CONFINED FIELD TRIALS (GENETICALLY MODIFIED ANIMALS, ANIMAL HEALTH INPUTS AND MICRO- ORGANISMS) This application form must be completed for each individual animal/organism species.

Applications for new and renewal of previously authorized contained or confined research field trials should be submitted separately.

Sections 1, 2 and 3 must be completed for all contained use (laboratory and animal units) trials.

For all confined field trials, Section 4 must be completed, in addition to Sections 1, 2 and 3.

Section 1: General Information 1.0 Title of Planned Introduction 1.1 Application Type 1.2 Animal/Organism Species Name 1.2.1 Latin Name(s) New Renewal 1.2.2 Common Name(s) [Issue 1] 56 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULEcontinued 1.3 Feed Section Indicate whether any animal/organism material generated in the contained or confined research trials will be used as research material for livestock feed Yes No 1.4 Applicant 1.5 Co-Applicant - Complete if the applicant is not a Kenyan resident 1.4.1 Name 1.5.1 Name 1.4.2 Address 1.5.2 Address (Affiliate Institution) 1.4.3 Telephone 1.4.4 Facsimile\ 1.5.3 Telephone 1.5.4 Facsimile/Email Email 1.6 Facility Manager (Name, Address and Telephone Number) 1.7 Name of Institutional Biosafety Committee (IBC) - (Attach confirmed minutes of IBC) 1.8 The Proposed Contained or Confined Trial 1.8.1 Brief description of proposed trial 1.8.2 What are the aims and objectives of the proposal? 1.8.3 What is the intended eventual use(s) of the products? Description of the Unmodified Animal/Organism 1.9 Fertility 1.9.1 Describe mechanisms and frequency of intra and inter-specific out-crossing 1.9.2 Describe the mechanism of infertility 1.10 Habitat 1.10.1 What is the natural habitat of the parent animal/organism and its distribution in Kenya? 1.10.2 Where is the origin of the parent animal/organism? 1.10.3 Is the parent animal/organism already present at or near the site of the planned genetically modified organism introduction(s)? 1.10.4 Is the parent animal/organism exotic to Kenya? 1.10.5 Does the unmodied form(s) have any adverse effect on: (please indicate adverse effects) 57 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] THIRD SCHEDULEcontinued 1.10.5.1 Humans, animals, or plants? 1.10.5.2 Agricultural production? (e.g.

pests) 1.10.5.3 Any other aspect of the environment? (e.g.

invasiveness) 1.10.5.4 List any locations in Kenya or elsewhere where the animal/organism is a known pest.

1.11 Phenotypic Characteristics Provide information on animal/organism mechanisms responsible for: 1.11.1 Tendency to propagate uncontrollably 1.11.2 Dormancy 1.11.3 Body tissues/fluid dispersal (animals only) 1.11.4 Persistence or dispersal of reproductive structures such as larvae and eggs 1.11.5 Other dispersal mechanisms 1.12 Toxins 1.12.1 List any known toxins produced by this animal/organism, including natural defence compounds 1.12.2 Indicate the levels at which these compounds induce toxicity 1.12.3 Indicate the species affected by these toxins 1.13 Allergens 1.13.1 List any known allergens that emanate from this animals/organisms, including natural defence compounds.

1.14 Please describe any other pathological, ecological and physiological traits that relate to the animal/organism Novel Trait (NT) but not the unmodified animal/organism.

A few suggestions of the required information are as described below: Generation time in natural ecosystems, sexual and asexual reproductive cycle Pathogenicity: infectivity, virulence, infective dose, communicability, possibility of survival outside of human, (toxigenicity, allergenicity = already given), carrier (vector) or means of dissemination of pathogen, biological stability, host range including non-target organisms.

Possible activation of latent viruses (proviruses), availability of possible therapies, etc.

Antibiotic resistance and potential use of the antibiotics in humans and domestic organisms Involvement in environmental processes, e.g.

primary production, nutrient turnover, decomposition of organic matter, etc [Issue 1] 58 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULEcontinued Section 2: Submission Please fill out Section 2 for each individual Submission included in the application.

2.1 Name or Designation of animal or organism Novel Trait (NT) 2.2 Novel Trait(s) Identification (Tick as appropriate) Genetic Research.

Pharmaceutical.

Generation of mutants.

Insect Resistance.

Stress Tolerance.

Fungal Resistance.

Nutritional change.

Increased production of Genes knocked out to allow milk or wool.

xenotransplantation.

Faster, more efficient growth Increased tolerance to cold Improved meat, milk or wool rates.

water for fish.

quality.

Leaner, more tender beef Resistance to diseases Milk that lacks allergenic and pork.

caused by viruses, bacteria proteins, or results in and other pathogens.

increased amounts of cheese and yogurt.

Development of animals that Possession of characteristics In the phylogenetic analysis serve as models for human which are environmentally of the amplified nucleic acid diseases to help scientists friendly e.g.

improved use of sequences to provide novel better understand prevention dietary phosphorous to information on the evolution and treatment strategies.

lessen the environmental of pathogens.

impacts of animal manure.

Animal vaccines rationally Development of diagnostic In epidemiology to characterize designed for the specific kits that can not only be pathogens through control and eradication of used in the laboratory but determination of their nucleotide diseases, including the pen-side tests that can be sequence.

The possibility of implementation of DIVA used in the field to make pinpointing the source of (differentiating infected from decisions about the infection can significantly vaccinated animals) exposure of animals during contribute to improved disease strategies.

a disease outbreak.

control.

Cloning to enable the rapid Cloning to help salvage the New and improved medicines dissemination of superior germplasm of indigenous for animals.

e.g.

Gene genotypes from nucleus species that are near therapy which involves the breeding flocks and herds, extinction, including intra- insertion of a functional gene directly to commercial species nuclear transfer or another molecule that farmers.

Genotypes could procedures which can be contains an information be provided that are ideally used to rescue genes from sequence into a cell to suited for specific product endangered species.

achieve a therapeutic effect.

characteristics, disease Thus, the gene serves as a resistance, or environmental drug.

conditions.

Producing large amounts of In the development of novel Other (Specify) therapeutic proteins in animal diagnostic assays, e.g.

milk or meat (biopharm PCR and isothermal animals or transgenic animal amplification methods, bioreactors) may be an microarrays, protein efficient, relatively low cost detection by nucleic acid method to manufacture many amplification, recombinant proteins used to treat human proteins, synthetic proteins, diseases or proteins that have biosensors etc.

to detect industrial value.

the pathogens and/or the immune responses after infection.

59 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] THIRD SCHEDULEcontinued 2.3 Novel Trait(s) Describe each specific novel trait associated with this animal or organism.

2.4.

Is GMO Imported or generated locally.

2.4.1 Import Permit No.

If the animal or organism novel trait is imported, provide the import permit number issued under the Animal Diseases Act (Cap 364) or any other appropriate legislation.

2.5 History Has this genetically modified organism been previously tested in Kenya? If yes, please provide information on trial(s), year(s) of authorization and location(s) tested.

Yes No 2.6 Trait Introduction and Selection Method 2.6.1 Describe Induction Method (mutagenesis) or Transformation Method (recombinant techniques).

2.6.2 Describe Selection Method.

2.6.3 Describe Mode of action of traits (gene product, metabolic pathways).

2.6.4 Other Provide details of modification by means other than mutagenesis or recombinant techniques.

2.7 Gene Donor Indicate the genes donor organism (for animals or organisms transformed using recombinant techniques).

2.8 Transformation Plasmids Please provide the following information: 2.8.1 Name of plasmid (construct) and genetic map (map of each genetic construct required).

2.8.2 Is the vector naturally 2.8.3 Is the vector 2.8.4 If yes, how was the vector pathogenic? (Tick as disarmed? disarmed? appropriate) (Tick as appropriate) Yes Yes No No [Issue 1] 60 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULEcontinued 2.8.5 For each gene construct, describe all genes, regulatory elements, gene products, non- translated nucleic acid (DNA/RNA) sequences and, where applicable, affected metabolic pathways.

2.8.5.1 Description of elements of the constructs(s): This area should be filled for all constructs and GMO gene elements 2.8.5.1.1 Genetic 2.8.5.1.2 Size (bp) 2.8.5.1.3 Source 2.8.5.1.4 Function Element 2.9 Characteristics of the Novel Trait(s) 2.9.1 Spatial and Temporal Trait Expression Trait Expression 2.9.1.1 Constitutive 2.9.1.2 Is the trait 2.9.1.3 Is the trait (Yes/No) expressed during inducible? specific If not constitutive, developmental If yes, how? indicate the stage? specific tissue(s) in which the trait is If yes, when? expressed (green tissue, seed, pollen, roots, other) 2.10 Toxicity and Allergenicity of the Novel Trait(s) 2.10.1 To what extent are novel gene products toxic when ingested by native faunal populations, including mammals, birds, reptiles, and insects? How has this been determined? 2.10.2 To what extent are novel gene products allergens? How has this been determined? 2.11 Altered Animal or Organism Characteristics Please indicate any changes with respect to the following: 2.11.1 Tendency to propagate uncontrollably 2.11.2 Dormancy 2.11.3 Body tissues/fluid dispersal (animals only) 2.11.4 Persistence or dispersal of reproductive structures such as larvae and eggs 61 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] THIRD SCHEDULEcontinued 2.11.5 Other dispersal mechanisms 2.11.6 What is the frequency of reversion, i.e., loss of genetic modication? 2.11.7 How do you verify that you have the desired GMO? 2.11.8 What methods are to be used to test for batch-to-batch consistency? 2.12 Facility Inspection 2.12.1 Has the facility been inspected by the relevant regulatory agency? Yes No Please attach the facility inspection approval letter/certificate 2.13 Trial Site Locations and Trial Protocols Town and Province Legal land and location Trial Protocol(s) Attach trial Protocol Please note: Section 3 must be completed for each Trial Protocol listed above and, for confined field trials.

Section 4 must be completed for each Trial Site Location listed above.

Section 3: Contained Use Trial Protocol Please fill out Section 4 for each Trial Protocol included in the application.

3.1 Trial Protocol (Study) Title: 3.2 Protocol Describe fully the purpose of the trial, the experimental design, the nature and type of data to be collected and arrangements for transporting the GMO to the trial site.

Please include proposed, if any, herbicide/pesticide use 3.3 Provide work schedule (post approval) to include: 3.3.1 Intervention (anticipated) 3.3.2 Sampling (anticipated) 3.4 Isolation State the isolation measures being implemented for this trial and give details 3.5 Method of introduction of GMO into parent where applicable [Issue 1] 62 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULEcontinued 3.6 Spraying/Dipping* Please complete this section if the trial site is subject to the use of an unregistered product, or a registered product used for a non-registered purpose.

3.6.1 Name of the pesticide 3.6.2 Total area sprayed (Square meters) 3.6.3 Active ingredient 3.6.4 Unregistered Pesticide Use Indicate whether the trial site location will be Yes No subject to unregistered pesticide use.

3.7 Harvesting 3.7.1 Will animal/organism be 3.7.2 Describe the method of harvest for microbial cultures, allowed to reproduce? embryos and other animal material Yes No 3.7.3 Will any material be 3.7.4 If yes, retained from the trial? 3.7.4.1 Type of material to be retained Yes No 3.7.4.2 Quantity to be retained 3.7.4.3 Purpose of retaining material.

3.7.5 Describe the storage method and storage location of harvested material 3.7.6 Provide the name, address and phone number of the contact person responsible for the storage of the material and the proposed storage records 3.7.7 Describe your management plan to avoid escape of GMO from the trial site 3.8 Disposal Plan 3.8.1 Describe your disposal plan for all material; including how and where the material will be disposed of 3.8.2 Provide the name, address and phone number of the contact person responsible for the disposal of the material and the proposed disposal records.

* This information is also required to determine compliance with the Pest Control Products Act 63 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] THIRD SCHEDULEcontinued 3.9 Contingency Plans 3.9.1 Describe your contingency plan in the case of accidental release of GMO material or the breakdown of isolation/quarantine 3.10 Monitoring the Trial Site 3.10.1 Describe the extent and frequency of trial site monitoring during the course of the trial 3.10.2 Describe the extent and frequency of trial site monitoring during the post-trial period 3.10.3 Describe what monitoring results will be recorded, how they will be recorded and who is responsible for them 3.10.4 If any controlled monitoring procedures are proposed for this trial, detail these 3.10.5 Describe the provisions to remove or eliminate the GMO from the test site or any other place where it may be found upon completing the trial release and to restore the test site and any such other place to its status quo Section 4: Field Trial Site Location (To be completed for confined field trials only) Please fill out Section 3 for each Trial Site Location included in the application.

4.1 Town/City 4.2 Province 4.3 Legal Land Location (The NBA will (Nearest city) not authorize a confined field trial unless the trial site has been inspected and approved) 4.4 Field Manager (Must be a Kenyan resident 4.5 Trial Size and responsible for the trial site location) Trial size in meters2 4.4.1 Name 4.4.2 Address 4.6 Map location Has a complete map location of the trial site been provided? Yes No [Issue 1] 64 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULEcontinued 4.4.3 Telephone 4.4.4 Facsimile A map and GPS coordinates of the trial site must be received by the NBA within 7 days following commencement of the trial.

4.7 Habitat 4.7.1 Describe the biological diversity of the trial site, including: 4.7.1.0 Potential impacts resulting from the field test 4.7.1.1 Soil 4.7.1.2 Groundwater level 4.7.1.3 Topography 4.7.1.4 Flora and fauna 4.7.1.5 Climate, especially prevailing winds and temperature 4.7.1.6 Former use of the facility 4.7.1.7 Distance from nearest human settlements 4.7.1.8 Distance from surface water body 4.7.2 Is the trial site part of a4.7.3 If yes, how close is the nearest natural managed ecosystem? ecosystem? Yes No 4.7.4 How close is the site from an area of special ecological interest, including protected areas and sanctuaries? 65 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] THIRD SCHEDULEcontinued 4.8 Indigenous Species 4.8.1 Specify the related wild and domesticated species/organisms present at the trial site and how close they are to the novel animal/organism material under test 4.8.2 Are there any endangered species on 4.8.3 If yes, please list or near the site? Yes No For information on endangered species that may be near the trial site location, contact the Kenya Wildlife Service, P.O.

Box 40241 NAIROBI, Email: kws@kws.org, Website: www.kws.org, Langata Road, Telephone (+245-20-501081).

4.8.4 What mechanisms are in place to prevent the local fauna from removing novel plant/animal/organism material from the site? 4.9 Post-Trial Land Use 4.9.1 Name and address of the person(s) having control over the site during the post-trial land use period 4.9.2 What is the anticipated post-trial land use? 4.9.3 Describe how the site boundaries will be marked to facilitate subsequent inspection 4.10 Submissions and Trial Protocols Please list all submissions and trial protocols used at this site.

Submission (Animal or organism novel trait designation List of possible designations/unique Trial Protocol(s) identifier) Please note: Section 2 must be completed for each Submission listed above and Section 4 must be completed for each Trial Protocol listed above.

4.11 Public Notice 4.11.1 How will you provide public notification of your proposed field trial? [Issue 1] 66 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULEcontinued Section 5: Certification I certify that the above information is true to the best of my knowledge.

Principal Investigator Name.

Signature.

Date.

Collaborator(s) Name(s).

Signature.

Date.

Collaborator(s) Name(s).

Signature.

Date.

Collaborator(s) Name(s).

Signature.

Date.

Institutional Biosafety Committee (IBC) Review This application has been reviewed by IBC Name of IBC.

Name of chairperson.

Signature.

Date.

PART III APPLICATION FORM FOR CONFINED FIELD TRIAL (PLANTS) This application form must be completed for each individual genetically modified plant.

The application may include more than one submission of a genetic modification of that particular species, Trial site Location and/or Trial Protocol.

Complete section 2 for each submission, section 3 for each trial site and section 4 for each trial protocol included in the application.

All sections must be completed.

Additional pages can be attached if the space provided is not sufficient.

Applications for new and renewal of previously authorized confined research field trials should be submitted separately.

Section 1.0 General Information 1.1 Application Type 1.2 Plant Species Name 1.2.1 Latin Name(s) New Renewal Date of submission of the application 1.2.2 Common Name(s) (Indicate if perennials, annuals, trees etc.) 67 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] THIRD SCHEDULEcontinued 1.3 Feed Section Indicate whether any plant material generated in the confined field trials will be used as research material for livestock feed Yes No 1.4 Applicant 1.5 Name of Institutional Biosafety Committee.

1.4.1 Name (Attach signed minutes of Institutional Biosafety Committee discussions) 1.5.1 Institution of applicant 1.5.2 Registration Status in Kenya 1.5.2.1 Affiliating institution (if institution of applicant is not registered in Kenya) 1.4.2 Address 1.5.3 Address 1.4.3 Telephone 1.4.4 Facsimile/email 1.5.3 Telephone 1.5.4 Facsimile/email 1.6 Summary of trial 1.6.1 Brief Description of Proposed Trial 1.6.2 Objective 1.6.3 What is the aim of the proposed trial of the genetically modied organism? 1.6.4.

What are the benets of this approach compared with other possible methods, especially those not involving planned trial? 1.6.5 If the trial is successful, do you intend to propose a general release of the GMO? 1.6.6 Summary of the risk assessment 1.7 Description of unmodified plant species 1.7.1 Describe mechanisms and frequency of intra-and inter-specific out-crossing [Issue 1] 68 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULEcontinued 1.7.2 Describe the mechanism of infertility 1.8 Phenotypic Characteristics Provide information on plant mechanisms responsible for: 1.8.1 Tendency to weediness 1.8.2 Allelopathy 1.8.3 Dormancy 1.8.4 Pollen dispersal 1.8.5 Seed dispersal 1.8.6 Vegetative dispersal 1.8.7 Other dispersal 1.8.8 Other Characteristics 1.9 Toxins 1.9.1 List any known toxins from this species, including natural defence compounds 1.9.2 Indicate the levels at which these compounds induce toxicity 1.9.3 Indicate the species affected by these toxins 1.10 Allergens 1.10.1 List any known allergens for this species, including natural defence compounds 1.11 Describe any pathological, ecological and physiological traits that relate to the genetically modified organism but not to the unmodified plant Section 2: Submission Fill out section 2 for each individual submission (genetic modification of that particular species) included in the application.

2.1 Name or Designation of genetically modified organism 69 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] THIRD SCHEDULEcontinued 2.2 Modified trait(s) Identification Herbicide Tolerance Modified Oil Composition Pharmaceutical Male sterility/restoration Virus Resistance Genetic Research Insect Resistance Stress Tolerance Generation of mutants Nutritional change Fungal Resistance Other (Specify) 2.3 Modified Trait(s) Describe each specific novel trait associated with this genetically modified organism.

2.4 Status of authorization 2.4.1 Is genetically modified organism Imported or generated locally? 2.4.2 If imported, provide the import permit number issued under any other authorization 2.5 History Has this Genetically Modified Organism been previously tested in Kenya? Yes No If yes, please provide information on trial(s), year(s) of authorization and location(s) tested.

2.6 Trait Introduction and Selection Method 2.6.1 Describe Introduction Method(s) 2.6.2 Describe Trait Selection Method 2.6.3 Describe Mode of action of traits (gene product, metabolic pathways) 2.6.4 Other techniques of modification Provide details of modification by means other than mutagenesis or recombinant DNA techniques 2.7 Gene Donor(s) Indicate the gene donor organism(s) (for plants transformed using rDNA techniques) 2.8 Transformation Vectors and/or Plasmids Please provide the following information: 2.8.1 Name of plasmid (construct) and genetic map (map of each genetic construct required) [Issue 1] 70 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULEcontinued 2.8.2 Is the vector naturally 2.8.3 Is the vector disarmed? 2.8.4 If yes, how was the pathogenic? vector disarmed? Yes No Yes No 2.8.5 For each gene construct, describe all genes, regulatory elements, gene products, non- translated DNA sequences and, where applicable, affected metabolic pathways 2.9 Characteristics of the transformed Trait(s) 2.9.1 Spatial and Temporal Trait Expression Trait Expression 2.9.1.1 Constitutive 2.9.1.2 Is the trait 2.9.1.3 Is the trait expressed during inducible? Yes No specific developmental stage? If not constitutive, indicate the specific Yes No Yes No tissue(s) in which the If yes, when? If yes, how? trait is expressed (green tissue, seed, pollen, roots, other) 2.10 Toxicity and Allergenicity of the Transformed Trait(s) 2.10.1 To what extent are transformed gene products toxic when ingested by native fauna populations, including mammals, birds, reptiles, and insects? 2.10.1.1 How has this been determined? 2.10.2 To what extent are transformed gene products allergens? 2.10.2.1 How has this been determined? 2.11 Altered Plant Characteristics Please indicate any changes with respect to the following: 2.11.1 Persistence and invasiveness 71 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] THIRD SCHEDULEcontinued 2.11.2 Allelopathy 2.11.3 Dormancy 2.11.4 Pollen Dispersal 2.11.5 Seed Dispersal 2.11.6 Vegetative Dispersal 2.11.7 Any other Dispersal Mechanism 2.11.8 Any other altered characteristic(s) Are any of the likely gains directly linked to losses in other characteristics of the species? 2.11.9 Please describe if any toxins and allergens are produced by the GMO that were not produced by the unmodified plant 2.11.10 What is the frequency of reversion, i.e., loss of genetic modication? 2.11.11 How do you verify that you have the desired GMO? 2.11.12 What methods are to be used to test for batch-to-batch consistency? 2.12 Trial Site Locations and Trial Protocols 2.12.1 Town and Province 2.12.2 Legal land location 2.12.3 Trial Protocol(s) (Attach trial Protocol) Please note: Section 3 must be completed for each Trial Site Location listed above and Section 4 must be completed for each Trial Protocol listed above.

Section 3: Confined Field Trial Site Please fill out Section 3 for each Trial Site Location included in the application.

3.1 Town/City 3.2 Province 3.3 Legal Land Location (The National (Nearest city) Biosafety Authority will not authorize a confined field trial until the legal land location of the trial site has been given) [Issue 1] 72 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULEcontinued 3.4 Field Manager responsible for the trial site 3.4.2 Address 3.4.1 Name (Must be affiliated to a research institution registered in Kenya ) 3.4.3 Telephone 3.4.4 Facsimile 3.5 Trial Size 3.6 Location Map Trial size in meters2/Hectarage Attach a complete map (including GPS coordinates) of the location of the trial site 3.6.1 Has the suitability of the contained use facility to conduct contained use activity been assessed? Explain 3.7 Habitat 3.7.1 Describe the biological diversity of the trial site, including: 3.7.1.0 Potential impacts resulting from the field test 3.7.1.1 Soil 3.7.1.2 Groundwater level 3.7.1.3 Topography 3.7.1.4 Flora and fauna 3.7.1.5 Climate, especially prevailing winds direction and Temperate 3.7.1.6 Previous use of the facility 73 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] THIRD SCHEDULEcontinued 3.7.1.7 Distance from nearest human settlements 3.7.1.8 Distance from surface water body 3.7.2 Is the trial site part a of a managed 3.7.3 If yes, how close is the nearest natural ecosystem? ecosystem? Yes No 3.7.4 How close is the site from an area of special ecological interest, including protected areas and sanctuaries? 3.8 Indigenous Species 3.8.1 Specify the related wild and domesticated species/organisms present at the trial site and how close they are to the modified plant material under test 3.8.2 Are there any endangered species on or 3.8.3 If yes, list near the site? Yes No NB: For information on endangered species that may be near the trial site location, contact the Kenya Wildlife Service, P.O.

Box 40241 NAIROBI, Email: kws@kws.org, Website: www.kws.org, Langata Road, Telephone (+245-20-501081).

3.8.4 What mechanisms are in place to prevent the local fauna from removing the modified plants material from the site? 3.9 Post-Trial Land Use 3.9.1 Person(s) having control over the site during the post-harvest/trial land use period, including the isolation area 3.9.

1.1 Name 3.9.1.2 Address 3.9.1.3 Telephone 3.9.1.4 Facsimile [Issue 1] 74 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULEcontinued 3.9.2 Describe how the site boundaries will be marked to facilitate subsequent inspection 3.10 Submissions and Trial Protocols Please list all submissions and trial protocols used at this site 3.10.1 Submission (genetically modified 3.10.2 Trial Protocol(s) organism designation List of possible designations/unique identifier) Please note: Section 2 must be completed for each Submission listed above and Section 4 must be completed for each Trial Protocol listed above.

Section 4: Confined Field Trial Protocol Please fill out Section 4 for each Trial Protocol included in the application.

4.1 Trial Protocol (Study) Title: 4.2 Protocol 4.2.1 Fully describe the following 4.2.2 Purpose of the field trial 4.2.3 Experimental design 4.2.4 Nature and type of data to be collected 4.2.5 Arrangements for transporting the GMO to the trial site 4.2.6 Proposed, if any, herbicide/pesticide use 75 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] THIRD SCHEDULEcontinued 4.3 Provide work schedule (post approval) to include: 4.3.1 Planting (anticipated) 4.3.2 Harvest/Sampling (anticipated) 4.4 Isolation State the isolation measures being implemented for this trial and give details 4.4.1 If using bags or nets, please provide the mesh size of the material being used and justify the effectiveness 4.5 Seeding 4.5.1 Material will be planted by: 4.5.2 Will any unmodified plants of the same or a related species be planted at the trial site location? 4.5.1.1 Hand Or 4.5.3 If yes, state reason 4.5.1.2Mechanically 4.5.4 Describe your management plan to avoid the dissemination, e.g.

of seed, from the trial site 4.5.5 Describe your plan for recording the quantities of seed planted/GMO used and accounting for any excess 4.5.6 Describe the disposition plan, including how and where any excess, or non-planted seed/GMO will be disposed of or stored 4.6 Spraying* Complete this section if the trial site is subject to the use of an unregistered product, or a registered product used for a non-registered purpose 4.6.1 Registered pesticide for unregistered use 4.6.1.1 Name of the pesticide 4.6.1.2 Total area to be 4.6.1.3 Active ingredient 2 sprayed (m hectarage) 4.6.2 Unregistered Pesticide Use Yes No 4.6.2.1 Name of the pesticide 4.6.2.2 Total area to be sprayed 4.6.2.3 Active ingredient 2 (m /hectarage) [Issue 1] 76 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULEcontinued 4.7 Harvesting 4.7.1 Will plants be allowed to 4.7.2 Describe the method of harvest for seed and other plant set seed or to reproduce? material (e.g.

by hand, small plot combine, etc.) Yes No 4.7.3 Will any harvested plant 4.7.4 Material retention If yes material be retained from the trial? 4.7.4.1 Type (e.g.

seed, leaves, etc.) Yes No 4.7.4.2 Quantity to be retained 4.7.4.3 Purpose of retaining material 4.7.5 For harvested plant material, describe the following if applicable: 4.7.5.1 The storage method 4.7.5.2 Storage location 4.7.6 Person responsible for the storage of the material 4.7.6.1 Name 4.7.6.2 Address 4.7.6.3.

Telephone 4.7.6.4 Facsimile 4.7.6.5 Proposed storage records 4.7.7 Describe how the site boundaries will be marked to facilitate subsequent inspection 4.7.8 Describe your management plan to avoid dissemination of seed/GMO from the trial site during harvesting 4.8 Disposal 4.8.1 Describe your disposal plan for all propagules and non-propagule plant material; including how and where the material will be disposed of 4.8.2 Person responsible for the disposal of the material 4.8.2.1 Name 4.8.2.2 Address 77 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] THIRD SCHEDULEcontinued 4.8.2.

Telephone 4.8.2.4 Facsimile 4.8.2.5 Proposed disposal records 4.9 Contingency Plans 4.9.1 Describe your contingency plan in the case of accidental release of seed/GMO plant material (e.g.

spills), or the breakdown of isolation 4.9.2 Describe your contingency plans if after accidental release there is unexpected spread of the transformed plant material 4.10 Monitoring the Trial Site 4.10.1 Describe the extent and frequency of trial site monitoring during the course of the field trial 4.10.2 Describe the extent and frequency of trial site monitoring during the post-trial period 4.10.3 Person responsible for monitoring 4.10.3.1 Describe what monitoring results will be recorded 4.10.3.2 Describe how monitoring results will be recorded 4.10.4 If any controlled monitoring procedures are proposed for this trial (e.g.

planting of unmodified plants of a related species to determine possibility and frequency of gene flow), detail these 4.10.5 Describe the provisions to remove or eliminate the GMO from the test site or any other place where it may be found upon completing the trial and to restore the test site and any such other place to its status quo 4.11 Public Notice 4.11.1 How will you provide public notification of your proposed field trial? * This information is required to determine compliance with the Pest Control Products Act (Cap 346).

[Issue 1] 78 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULEcontinued Section 5: Hectarage Please indicate the number of hectares per submission per province (Limit of 5 ha cumulative per submission per province) Province A: Submission (genetically modified organism designation) Trial site location Legal land location Town Number of hectares Total number of hectares: Province B: Submission (Genetically modified organism designation): Trial site location Legal land location Town Number of hectares Total number of hectares: Add other tables for any other Province, if applicable Section 6: Certification I certify that the above information is true to the best of my knowledge.

Principal Investigator Name.

Signature.

Date.

Collaborator(s) Name(s).

Signature.

Date.

Institutional Biosafety Committee (IBC) Review This application has been reviewed by IBC Name of IBC.

Name of chairperson.

Signature.

Date.

79 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] FOURTH SCHEDULE [Rule 9.] THE NATIONAL BIOSAFETY AUTHORITY APPROVAL TO CONDUCT CONTAINED USE ACTIVITY USING GENETICALLY MODIFIED ORGANISM APPROVAL NUMBER.

DATE OF ISSUE.

VALID UP TO.

In accordance with regulation 9 of the Biosafety (Contained Use) Regulations, of the Biosafety Act, I hereby grant the approval to undertake contained use activity of the genetically modified organism herein stated in the research institution mentioned in this approval.

Name of the Applicant/ Research Institution Specification of the genetically modified organism Quantity approved Specification of the genetic modification Risk category Purpose of the use This approval is granted subject to the following conditions- 1.

This approval is not transferrable and is valid for: Place: Name:.

Date.

Signature:.

The Chief Executive Officer National Biosafety Authority FIFTH SCHEDULE [Rule 13, 14.] CONTINGENCY PLAN 1.0 Name of the Applicant 2.0 Address of the Work place 3.0 Accurate identification of premises, sites and facilities where the genetically modified organisms are used and the accurate identification of the place, premises, sites or facilities are situated (describe and attach map) [Issue 1] 80 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] FIFTH SCHEDULEcontinued 4.0 Plan of the workplace with identification of places that are important for the reduction of accident consequences, places of storage of genetically modified organisms, protective measures of the contained space 5.0 Description of an accident that can occur in space or place where the genetically modified organism is used 6.0 Review on possible accident impacts on human health and the environment, including the methods for detection of such impacts and effective protection from the impacts 7.0 Validated procedures for the detection of 8.0 Validated methods and procedures presence of genetically modified available for liquidation of genetically organisms modified organisms and for decontamination of an affected space 9.0 Methods of isolation of spaces and 10.

Methods of disposal or remediation of facilities affected by accident including plants and animals that were in the methods of control of isolation affected area at the time of the accident effectiveness 11.

Description and layout of decontamination agents available to liquidate genetically modified organisms and decontaminate an affected space 12.

Procedures for protection of human health and the environment in case of undesirable effects of an accident 13.

Description of the procedure of subsequent monitoring of sites and premises after the termination of a decontaminated process 14.

Persons to whom the contingency plan is 15.

Manner of notification of an accident to submitted to the Authority and relevant regulatory agency including the manner of warning the inhabitants on its possible consequences 16.0 Undertaking of the applicant (attach affidavit) 16.1 Name Signature.

81 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] FIFTH SCHEDULEcontinued DECLARATION BY APPLICANT I,.

of P.O.

Box No.

of (Company/ Institution).

ID No.

, hereby declare that to the best of my knowledge and belief the particulars given in this application are true and correct.

Declared by } this day of } DECLARANT at }.

Before me Commissioner for Oaths/Magistrate/Judge [Issue 1] 82 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] BIOSAFETY (IMPORT, EXPORT AND TRANSIT) REGULATIONS, 2011 ARRANGEMENT OF REGULATIONS PART I PRELIMINARY Regulation 1.

Citation.

Interpretation.

Objective.

PART II APPLICATIONS 4.

Application and requirements for import.

Unauthorized importation.

Application and requirements for export.

Application and requirements for transit.

Conditions for transit.

Unauthorized transit.

10.

Unintentional release while on transit.

11.

Approval.

PART III MISCELLANEOUS 12.

Monitoring for compliance.

13.

Genetically modified organisms register.

14.

Review of decisions.

15.

Registration of decisions in the National Biosafety Clearing House.

16.

Confidential information.

17.

Products derived from genetically modified organisms.

18.

Offences and penalties.

SCHEDULES FIRST SCHEDULE APPLICATION FORM FOR IMPORT, EXPORT AND TRANSIT OF GENETICALLY MODIFIED ORGANISMS SECOND SCHEDULE APPROVAL TO IMPORT/EXPORT/TRANSIT*GENETICALLY MODIFIED ORGANISMS THIRD SCHEDULE INFORMATION REQUIRED FOR SAFETY ASSESSMENT 83 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] BIOSAFETY (IMPORT, EXPORT AND TRANSIT) REGULATIONS, 2011 [L.N.

97/2011.] PART I PRELIMINARY 1.

Citation These Regulations may be cited as the Biosafety (Import, Export and Transit) Regulations, 2011.

Interpretation In these Regulations unless the context otherwise requires accident means the unintended release of genetically modified organisms in the course of import, export or transit, which could pose present an immediate or delayed hazard to human health and the environment; Authority means the National Biosafety Authority established under section 5 of the Act; Biosafety Clearing House means a mechanism for exchange of scientific, technical, environmental, socio-economic and legal information and experience with genetically modified organism; competent authority means an agency of another country responsible under its national law for the control or regulation of genetically modified organisms; contained use means any activity undertaken within a facility, field, installation or other physical structure, which involves genetically modified organisms that are controlled by specific measures to provide safety for humans and the environment; contained use premises includes a facility, field, installation or other physical structure in which contained use is undertaken; environmental release means introduction into the environment of a genetically modified organism for which an approval has been granted in accordance with the Biosafety (Environmental Release) Regulations, 2011; export means to take out of Kenya a genetically modified organism; genetically modified organism means an organism that possesses a novel combination of genetic material obtained through the use of modern biotechnology techniques; import means to bring into Kenya a genetically modified organism; transit means the movement of genetically modified organism through Kenya to another country.

Objective The objective of these Regulations is to ensure safe movement of genetically modified organisms into and out of Kenya while protecting human health and the environment.

[Issue 1] 84 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] PART II APPLICATIONS 4.

Application and requirements for import (1) A person wishing to import a genetically modified organism shall apply for and obtain written approval from the Authority.

(2) An application to import a genetically modified organism shall be in the form set out in the First Schedule to these Regulations and shall be accompanied by (a) a cover letter; and (b) an application fee of twenty five thousand shillings.

(3) An application under Regulation 4 shall specify (a) the species or identity and amount of the genetically modified organism proposed to be imported; and (b) the proposed port of entry into Kenya; (c) the intended purpose for the genetically modified organism: Provided that (i) where the intended purpose is for contained use the provisions of the Biosafety (Contained Use) Regulations, 2011 shall apply; (ii) where the intended purpose is for the environmental release the provisions of the Biosafety (Environmental Release) Regulations, 2011 shall apply.

(4) The Authority may opt not to undertake risk assessment in cases where it previously gave approval for importation of the same genetically modified organisms from the same source.

(5) A person who contravenes subregulation (1) of this regulation commits an offence.

Unauthorized importation In the event of an import of a genetically modified organism for which no authorization has been granted, the Authority (a) shall initiate remedial action such as refusal of entry, destruction or set conditions of use; and (b) may inform and advise the public, of the existence of the genetically modified organism within the country.

Application and requirements for export (1) A person wishing to export a genetically modified organism shall apply for and obtain written approval from the Authority.

(2) An application to export a genetically modified organism shall be made to the Authority in the form set out in the First Schedule and shall be accompanied by (a) consent or approval for import issued by the competent authority of the importing country; and (b) an application fee of twenty five thousand shillings.

(3) An application to export genetically modified organisms shall specify (a) the species or identity and amount of the genetically modified organism that is to be exported; and (b) the proposed port of exit from Kenya.

(4) The Authority shall, upon receipt of an application under this regulation, confirm that the proposed export meets the requirements of the importing country and may issue the approval in the manner prescribed in the Second Schedule.

85 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] (5) The Authority shall give a copy of the approval to the relevant regulatory agency for authorization of export.

(6) A person who contravenes sub regulation (1) of this regulation commits an offence.

Application and requirements for transit (1) A person wishing to transit a genetically modified organism shall apply for and obtain written approval from the Authority.

(2) An application under subregulation (1) shall be in the form set out in the First Schedule.

(3) A person transiting a genetically modified organism shall ensure that the genetically modified organisms are packaged and transported in accordance with Kenyan and International standards.

(4) A person who contravenes subregulation (1) commits an offence.

Conditions for transit (1) A person transiting a genetically modified organism shall provide a copy of the approval granted by the Authority at the port of entry and exit.

(2) An approval to transit shall include (a) approved methods for packaging and handling of genetically modified organisms imported through conveyor shipment which should comply with the relevant international and national requirements for repackaging and handling of conveyor shipped commodities; (b) a requirement that conveyor shipment shall meet import conditions under these Regulations; and (c) a copy of the import permit issued by the receiving country indicating the quantities or volumes involved from the country of origin and confirming that the consignment may contain genetically modified materials.

(3) The Authority shall liaise with the relevant regulatory agency to ascertain that the consignment at the port of entry and exit is consistent with accompanying documents.

Unauthorized transit If a person transits or is in the process of transiting a genetically modified organism for which no approval has been granted, the Authority may (a) confisticate the genetically modified organism; (b) destroy the genetically modified organism; or (c) set conditions for transit of the genetically modified organism; and (d) inform and advice the public on the genetically modified organism.

10.

Unintentional release while on transit (1) In the event of an accident involving a genetically modified organism on transit it shall be the responsibility of the person transiting and the importer to (a) notify the Authority immediately both verbally and in writing of the accident; and [Issue 1] 86 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] (b) as soon as possible provide the Authority with information regarding (i) the circumstances of the accident; (ii) the identity and the quantity of genetically modified organism released; (iii) the type of accident; and (iv) any emergency measures taken or that ought to be taken to avoid or mitigate any adverse effects of the accident; (c) take all appropriate short term, medium term and long term measures to avoid or mitigate any adverse effects of the accident.

(2) The Authority shall inform and advise the public of the accident.

(3) The Authority in consultation with the relevant regulatory agency shall undertake necessary action to minimize risk to human health and environment.

11.

Approval An approval granted by the Authority under these Regulation shall be in the form set out in the Second Schedule to these Regulations.

PART III MISCELLANEOUS 12.

Monitoring for compliance The Authority shall liaise with the relevant regulatory agency to monitor any imported genetically modified organisms for compliance with the requirements of these Regulations.

13.

Genetically modified organisms register The Authority shall maintain a register, which shall contain all applications made to and decisions made by the Authority regarding genetically modified organisms.

14.

Review of decisions Where the Authority or a person granted an approval under these Regulations considers that (a) a change in circumstances has occurred which may influence the approval or the conditions issued under the approval; or (b) additional relevant scientific or technical information has become available, the Authority may on its own volition or on the request of the person granted the approval, review its decision.

15.

16.

Confidential information (1) The Authority shall not disclose to a third party any confidential information exchanged under these Regulation and shall protect the intellectual property rights of the applicant.

(2) The applicant may indicate, with verifiable justification, information in the application the disclosure of which might harm the competitive position of the applicant and which should be kept confidential.

87 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] (3) The following information shall not be considered confidential (a) the name and address of the exporter and importer; (b) the unique identifier of the genetically modified organism; (c) a summary of the risk assessment; and (d) any method and plans for emergency response.

(4) Where an applicant withdraws an application, the authority shall respect the confidentiality of the information supplied.

17.

Products derived from genetically modified organisms (1) A person intending to export, import or transit a product derived from genetically modified organisms whose safety has been established in accordance with Kenya Standards for food and feed safety assessment shall notify the Authority in writing indicating proof of safety.

(2) The information required under subregulation (1) shall be provided in the format prescribed in the Third Schedule.

(3) Upon receipt of such notification, the Authority shall, in consultation with the relevant regulatory agency, review the information provided and communicate its decision.

18.

Offences and penalties A person who contravenes the provisions of these Regulations commits an offence and is liable on conviction to a fine not exceeding twenty million shillings or to imprisonment for a term not exceeding ten years or both.

FIRST SCHEDULE [Rules 4(2), 6(2), 7(2).] APPLICATION FORM FOR IMPORT, EXPORT AND TRANSIT OF GENETICALLY MODIFIED ORGANISMS 1.

Name, address (including physical address) Type of application (Tick as appropriate) and contact details of the importer/exporter Import Export Transit 2.

Contact details of the competent authority as 2.1 Importing/Destination country applicable 2.2 Exporting country 3.

Name, address and contact details of the 4.

Country of origin supplier 5.

Expected date of import/export/transit [Issue 1] 88 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] FIRST SCHEDULEcontinued 6.

Common name, scientific name, commercial 7.

Port: name or unique identifier code of the genetically modified organism 7.1 Entry into Kenya 7.2 Exit from Kenya 8.

Evidence of approval of the genetically 9.

Consent for import from the destination modified organism from the exporting country.

country (in case of export or transit) (Attach) 10.

The intended use of the genetically modified 11.

The quantity of the genetically modified organism in Kenya and what it was used for in organism to be imported into Kenya the exporting country 12.

A summary of the risk assessment report 13.

Methods and plans for safe handling, storage, transport and use, including packaging, labelling, documentation, disposal and contingency procedures 14.

Describe the emergency response plan in Kenya in the event of an accident with the genetically modified organisms DECLARATION BY APPLICANT I,.

of P.O.

Box No.

of (Company/ Institution).

ID No.

hereby declare that to the best of my knowledge and belief the particulars given in this application are true and correct.

Declared by } this day of } DECLARANT At }.

Before me Commissioner for Oaths/Magistrate/Judge 89 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] SECOND SCHEDULE [Rules 4(1), 6(4), 7(1), 11.] APPROVAL TO IMPORT/EXPORT/TRANSIT* GENETICALLY MODIFIED ORGANISMS APPROVAL NUMBER.

DATE OF ISSUE.

VALID UP TO.

In accordance with regulation 4, 6, 7 and 11 of the Biosafety (Import, export end transit) Regulations 2011, approval is hereby granted to export, import or transit* the genetically modified organism herein stated.

The approval is granted to the applicant mentioned in this approval.

1.0 Name of the Applicant 2.0 To import/export/transit from/to 2.1 Name and address of supplier: 2.2 Country of supplier: 2.3 Country of destination: 3.0 Identity of the genetically modified organism 4.0 Specification of the genetic modification.

5.0 Quantity approved 6.0 Purpose This approval is granted subject to the following conditions 1.

7.0 The applicant should meet the following requirements for conveyor shipment 1.

Name: Place: Signature: Date The Chief Executive Office National Biosafety Authority Note: The applicant shall make samples available to the Authority on request This approval is not transferrable Ensure that any other relevant legal requirements have been met * Please delete as appropriate [Issue 1] 90 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] THIRD SCHEDULE [Rule 17(2).] INFORMATION REQUIRED FOR SAFETY ASSESSMENT 1.

Name, address (including physical address) Type of application (Tick as appropriate) and contact details of the Applicant include Import email and telephone Export Transit Other 2.

Contact details of the competent authority 2.1 Importing/Destination country responsible for safety assessment 2.2 Exporting country 3.

Name, address and contact details of the 4.

Country of origin supplier 5.

Expected date of import/export/transit 6.

Name of manufacturer or distributor if different 7.

Port: from applicant 7.1 Entry into Kenya 8.0 Description of the Product and its intended 7.2 Exit from Kenya use 9.0 Evidence of prior approval for use as 10.

Instructions and conditions of use, storage food/feed and source or indication of where detailed information on the approval can be obtained 11.

Quantity of the product 12.

Proposed labeling and packaging 91 [Issue 1] [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] BIOSAFETY (ENVIRONMENTAL RELEASE) REGULATIONS, 2011 ARRANGEMENT OF REGULATIONS PART I PRELIMINARY Regulation 1.

Citation.

Interpretation.

Objective.

Exceptions.

PART II APPLICATION FOR APPROVAL 5.

Environmental release.

Placing on the market.

Consideration of an application.

Non-assessment of risks.

Approval.

10.

Validity and renewal of approval.

11.

Handling of new information.

12.

Public awareness and participation.

13.

Decision document.

14.

Monitoring.

PART III MISCELLANEOUS 15.

Registration of decisions in the National Biosafety Clearing House.

16.

Confidentiality.

17.

Offences and penalties.

SCHEDULES FIRST SCHEDULE APPLICATION FORM FOR ENVIRONMENTAL RELEASE AND/OR PLACING ON THE MARKET OF GENETICALLY MODIFIED ORGANISMS SECOND SCHEDULE APPROVAL FOR ENVIRONMENTAL RELEASE/PLACING ON THE MARKET* OF A GENETICALLY MODIFIED ORGANISMS 93 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] BIOSAFETY (ENVIRONMENTAL RELEASE) REGULATIONS, 2011 [L.N.

98/2011.] PART I PRELIMINARY 1.

Citation These Regulations may be cited as the Biosafety (Environmental Release) Regulations, 2011.

Interpretation In these Regulations unless the context otherwise requires applicant means a person making an application under to these Regulations; Authority means the National Biosafety Authority established under section 5 of the Act; Biosafety Clearing-House means a mechanism for exchange of scientific, technical, environmental, socio-economic and legal information and experience with genetically modified organisms; environmental release means introduction into the environment of a genetically modified organism for which an approval has been granted in accordance with these Regulations and (a) for which no specific containment measures are used to limit their contact with and to provide a high level of safety for the general population and the environment; and (b) includes making genetically modified organisms available to the public for purposes other than sale; genetically modified organism means an organism that possesses a novel combination of genetic material obtained through the use of modern biotechnology techniques; placing on the market means making a genetically modified organism available for sale; regulatory agency means a regulatory agency as set out in the First Schedule to the Act, or such other agency as the Minister may, by order in the Gazette, determine; risk assessment means the evaluation of risks to human and the environment, whether direct or indirect, immediate or delayed, which the environmental release or placing on the market of genetically modified organisms may pose; screening for completeness means the evaluation of an application to ensure that all the administrative as well as technical requirements are met.

[Issue 1] 94 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] 4.

Exceptions These Regulations shall not apply to genetically modified organisms that are pharmaceuticals for human use.

PART II APPLICATION FOR APPROVAL 5.

Environmental release (1) A person shall not make an environmental release without the written approval of the Authority.

(2) An application for environmental release shall be made to the Authority in the form set out in Part A of the First Schedule to these Regulations and shall be accompanied by (a) an application fee of Kenya shillings eight hundred and fifty thousand; and (b) where necessary, an additional risk assessment report.

(3) An applicant may (a) refer to data or results from an application previously submitted by another applicant; or (b) submit additional information that the applicant considers relevant, provided that the information, data and results are non-confidential or such applicants have given their agreement in writing.

(4) The Authority may allow an application for release of the same genetically modified organism on the same site or on different sites for the same purpose and within a definite period to be made in a single application.

(5) Where the Authority, after a risk assessment, considers that it is necessary for the genetically modified organism to be subjected to contained use, the Authority shall communicate its decision to the applicant in writing and the provisions of the Contained Use Regulations shall apply.

(6) Where the application is for introduction into the environment of a genetically modified organism that is not locally developed, the Authority, after a risk assessment, may require that the applicant carries out field trials of the genetically modified organism and the provisions of the Contained Use Regulations shall apply.

(7) A person who contravenes sub- regulation (1) commits an offence.

Placing on the market (1) A person shall not place on the market a genetically modified organism without the written approval of the Authority.

(2) An application to place on the market a genetically modified organism shall be made to the Authority in the form set out in Part B of the First Schedule to these Regulations and shall be accompanied by (a) an application fee of Kenya shillings eight hundred and fifty thousand; and (b) where necessary, a risk assessment report.

(3) An applicant may (a) refer to data or results from an application previously submitted by other applicants; or (b) submit additional information that the applicant considers relevant, provided that the information, data and results are non-confidential or such applicants have given their agreement in writing.

95 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] (4) A person who contravenes subregulation (1) commits an offence.

Consideration of an application (1) Upon receiving an application, the Authority shall within fourteen days screen for completeness and circulate to the relevant regulatory agencies for further information, comments or reasoned objections.

(2) The Authority shall in considering an application, examine (a) the conformity of an application with the requirements of these Regulations; (b) the accuracy and completeness of the information given; (c) the risk assessment submitted by the applicant; and (d) the uses of the genetically modified organism.

(3) The authority shall publicize an application received hereunder and invite written comments from members of the public within twenty one days.

(4) Where necessary, the Authority may ask an applicant to provide further information.

(5) The Authority shall communicate its final decision to the applicant within one hundred and fifty days of receipt of the application, but not earlier than ninety days of such receipt.

(6) For the purpose of calculating the periods, any period of time during which the Authority is awaiting any further information that it may have requested from the applicant shall not be taken into account.

Non-assessment of risks (1) The Authority may opt not to undertake risk assessment where it determines that sufficient experience or information exists to conclude that an environmental release does not pose a significant risk.

(2) Once an approval has been granted by the Authority for release of a genetically modified organism, subsequent release of the same species, or the same species modified with the same gene or combination of genes, may be exempted from risk assessment.

Approval (1) An approval for environmental release shall be in the Form set out in the Second Schedule to these Regulations.

(2) If information becomes available that an approved activity poses a risk to human health or the environment, the Authority may amend or revoke the approval.

10.

Validity and renewal of approval (1) An approval granted under these Regulations shall be for a period not exceeding ten years.

(2) At least nine months before the expiry of an approval period, a person intending to continue to release into the environment or placing genetically modified organisms on the market shall submit an application for the renewal of the approval.

(3) An application for renewal of an approval under these Regulations shall contain the information set out in the First Schedule to these Regulations and shall be accompanied by (a) an application fee of eight hundred and fifty thousand shillings; [Issue 1] 96 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] (b) a copy of the approval under regulation 9(1); (c) a report on the results of the monitoring which was carried out in accordance with these Regulations; (d) any new information which has become available with regard to the risks of the genetically modified organism to human health and the environment; and (e) a proposal for amending or complementing the conditions of the original approval and any other conditions concerning future monitoring.

(4) The Authority shall consider an application for renewal within thirty days of receiving the application and may (a) approve the application with or without conditions; or (b) reject the application stating the reasons for rejection.

(5) Pending the renewal of an approval, an applicant may continue operating under the conditions of approval granted under regulation 9(1) until a final decision has been taken on the application for renewal.

(6) An approval for renewal from the Authority shall be valid for a period of ten years.

(7) Where a genetically modified organism has been released into the environment or placed on the market for twenty years with the approval from the Authority, and the Authority establishes that monitoring data indicates no risk to human health and the environment, the genetically modified organism may continue to be released to the environment or placed on the market without further approval.

11.

Handling of new information (1) Where there are any changes to a genetically modified organism or of a combination of genetically modified organisms as a result of the environmental release which could have adverse effects on human health and the environment after the Authority has given its written approval, the applicant shall immediately (a) take the measures necessary to protect human health and the environment; (b) inform the Authority in advance of any change or as soon as the unintended change is known or the new information is available; and (c) revise the measures specified in the application or approval.

(2) Where there are any changes to a genetically modified organism or of a combination of genetically modified organisms as a result of the environmental release which could have adverse effects on human health and the environment after the Authority has given its written approval the Authority (a) shall evaluate such information and may make it available to the public; and (b) may require the applicant to, modify the conditions of, suspend or terminate the environmental release.

12.

Public awareness and participation (1) The Authority shall promote public awareness and participation on the proposed environmental release.

(2) In carrying out public awareness and participation, the Authority shall publish guidance documents.

(3) The Authority shall (a) by notice in the Gazette; 97 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] (b) in at least two newspapers of wide circulation; and (c) on its website, make available to the public, non-confidential information on applications for environmental release of genetically modified organisms.

(4) Any person may within thirty days of the publication of a notice under paragraph (3), submit written comments on the proposed decisions for any application for placing a genetically modified organism on the market.

13.

Decision document (1) A decision on the application shall be recorded in a decision document.

(2) The decision document shall be in such form as the Authority may determine and shall contain a statement to the proposed manner of the use, risk management and proposed requirements for monitoring and shall include the following information (a) identification of properties of a recipient which are important for the use of the genetically modified organism; (b) any known risks to health and the environment arising from the introduction of non-modified recipient into the environment or on the market; (c) description of results of genetic modification in genetically modified organisms; (d) evaluation of the sufficiency of characterising genetic modification in the request to assess risks; (e) identification of risks to the health of humans, animals, plants and the environment which may arise from the use of genetically modified organisms in comparison with the use of corresponding non-modified organism, based on the risk assessment conducted; (f) a conclusion as to whether (i) a genetically modified organism may be released into the environment or placed on the market, and under which conditions, or (ii) a genetically modified organism shall not be released into the environment or placed on the market, in which case the reasons shall be stated.

14.

Monitoring (1) A person granted an approval under these Regulations together with the relevant regulatory agency shall monitor and report on the release in accordance with the approval.

(2) The relevant regulatory agency shall submit the monitoring report to the Authority.

(3) The Authority shall ensure that all appropriate measures are taken to avoid adverse effects on the health of humans, animals and the environment which might arise from the environmental release or the placing on the market of genetically modified organisms.

(4) The Authority shall develop and issue an inspection manual and guidelines to ensure that the relevant regulatory agency organises inspections and other control measures as appropriate for purposes of compliance with this regulation.

(5) In the event of a release of a genetically modified organism or the placing on the market of a genetically modified organism for which no approval has been granted, the Authority shall ensure that (a) necessary measures are taken to terminate the release or placing on the market of such organism; [Issue 1] 98 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] (b) remedial action is taken, if necessary; and (c) the public is informed and appropriately advised on such release or placing on the market.

PART III MISCELLANEOUS 15.

16.

Confidentiality (1) The Authority shall not disclose to a third party any confidential information exchanged under these Regulations and shall protect intellectual property rights of the applicant.

(2) An applicant may indicate with verifiable justification, information in the application submitted under these Regulations, the disclosure of which might harm the applicants competitive position and which should be treated as confidential.

(3) The Authority shall, after consultation with the applicant, decide which information may be kept confidential and shall inform the applicant accordingly.

(4) The following information shall not be considered to be confidential (a) the name and address of the applicant; (b) the general description of the genetically modified organism; (c) the purpose of the release; (d) the location of release and intended uses; (e) the plans for monitoring of the genetically modified organism and for emergency response; and (f) the risk assessment report.

(5) If, an applicant withdraws an application, the Authority shall respect the confidentiality of the information supplied.

17.

Offences and penalties A person who contravenes any of these Regulations commits an offence and shall be liable on conviction to a fine not exceeding twenty million shillings or to imprisonment for a term not exceeding ten years, or both.

FIRST SCHEDULE [Rule 5(2), 6(2),10(3).] APPLICATION FORM FOR ENVIRONMENTAL RELEASE AND/OR PLACING ON THE MARKET OF GENETICALLY MODIFIED ORGANISMS Part A of this schedule shall be filled by an Applicant making an application for either Environmental Release or Placing on the market of genetically modified organism(s), or both.

Part A and B of this schedule shall be filled by an Applicant making an application for Placing on the market of genetically modified organism(s).

99 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] FIRST SCHEDULEcontinued APPLICATION FORM FOR ENVIRONMENTAL RELEASE AND/OR PLACING ON THE MARKET OF GENETICALLY MODIFIED ORGANISM(S) PART A1.0 General information 1.1 Name of applicant 1.2 Physical Address 1.3 Telephone 1.4 Email 1.5 Title of the Application 1.6 Application Type of New Renewal 2.0 Information on the Genetically modified organism 2.1 Name and identity of the 2.2 Transformation event(s) genetically modified organism (Differences between the biological characteristics of the genetically modified organism and those of the recipient organism or parental organisms) 2.3 Intellectual property ownership of 2.4 Unique identifier for the genetically modified the novel trait, if any organism if any 2.5 Introduced or modified trait (Choose the trait from the following list) 2.5.1 Abiotic environmental tolerance 2.5.2 Altered growth, development and product quality Altered photoperiod sensitivity Altered ripening or flowering Cold or heat tolerance Coloration Drought or water tolerance Fertility restoration Other Growth rate or yield Male sterility Nutritional composition (including allergenicity) Selectable marker genes and reporter genes Uptake or degradation of environmental pollutants Other growth, development and product quality 2.5.3 Chemical tolerance 2.5.4 Medical products Herbicide tolerance Animal vaccines Other chemical tolerance Development of transplant organs Production of pharmaceuticals Other medical products [Issue 1] 100 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] FIRST SCHEDULEcontinued 2.5.5 Pest resistance 2.5.6 Other specify Bacterial resistance Fungus resistance Insect resistance Nematode resistance Virus resistance Other pest resistance 2.6 Technique used for modification.

(Please select techniques used for the transformation) Plasmid carried by Biolistic methods Agrobacterium tumefaciens Electric shock polarisation Osmotic shock Other- specify 2.7 Description of gene modification 2.8 Summary of contained use and confined field trial data (provide information on key results of trials at both contained level and confined field trials whether conducted in Kenya or outside Kenya) 3.0 Characteristics of genetic modification 3.1 Vector characteristics 3.1.1 vector(s) identity 3.1.2 source(s) or origin 3.1.3 host range 3.2 Insert or inserts (Genetic characteristics of the inserted nucleic acid and the function it specifies, and/or characteristics of the modification introduced) 3.3 Description of phenotypic 3.4 Rate and level of expression of the new genetic characteristics (in particular any material.

Method and sensitivity of measurement new traits and characteristics which may be expressed or no longer expressed) 3.5 Activity of the expressed protein(s) 3.6 Description of identification and detection techniques of the inserted sequence and vector 4.0 Recipient organism or parental organisms 4.1 Taxonomic name/status of 4.2 Common name of recipient organism or parental recipient organism or parental organisms organisms 4.3 Point of collection or acquisition 4.4 Center(s) of origin of the recipient organism or of parental organisms parental organisms (Describe the exact location and give geographical coordinates) 101 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] FIRST SCHEDULEcontinued 4.5 Center(s) of genetic diversity, if 4.6 Habitats where the recipient organism or Parental known, of Centres of genetic organism may persist or proliferate Diversity, if known, of Recipient organism or Parental organisms (Describe the exact location and give geographical coordinates) 4.7 Description of the habitat where the genetically modified organism may persist or proliferate 5.0 Donor organism(s) 5.1 Taxonomic name/status of the 5.2 Common name of donor organism donor organism or parental organisms 5.3 Point of collection or acquisition 5.4 Biological characteristics of donor organisms of donor organism (Describe the exact location and geographical coordinates) 6.0 Intended use and receiving environment 6.1 Description of the proposed deliberate release, including the purpose(s) and foreseen products 6.2 Foreseen dates of the release 6.3 Quantities of genetically modified organisms to be released 6.4 Suggested method(s) for safe handling, transport and storage during release 6.5 History and results of previous environmental releases, as well as uses of the genetically modified organism (country, region, dates of releases especially at different scales and in different ecosystems, any adverse effects on the health of human, animal and plant, and environment) 6.6 Intended use of the Genetically 6.7 Receiving environment modified organism (Information on the location, geographical, climatic (Information relating to the and ecological characteristics, including relevant intended use of the genetically information on biological diversity and centres of modified organism, including new origin of the likely potential receiving environment) or changed use compared to the recipient organism or parental organisms) 7.0 Risk assessment summary (Cite references) 7.1 Detection/Identification method of the genetically modified organisms (Suggested detection and identification methods and their specificity, sensitivity and reliability) [Issue 1] 102 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] FIRST SCHEDULEcontinued 7.2 Evaluation of the likelihood of adverse effects (An evaluation of the likelihood of these adverse effects being realized, taking into account the level and kind of exposure of the likely potential to the health of human, plant and animal, and the receiving environment to the genetically modified organism) 7.3 Evaluation of the consequences (An evaluation of the consequences should these adverse effects be realized) 7.4 Overall risk (An estimation of the overall risk posed by the genetically modified organism based on the evaluation of the likelihood and consequences of the identified adverse effects being realized) 7.5 Recommendation (A recommendation as to whether or not the risks are acceptable or manageable, including, where necessary, identification of strategies to manage these risks) 7.6 Information on post release monitoring and emergency response plans (describe post release monitoring methods, recall procedures) 8.0 Additional information 8.1 Availability of detailed risk assessment information (Please indicate whether more details on the risk assessment are available and how they can be accessed) 8.2 Any other relevant information 8.3 Additional notes PART B1.0 General information 1.1 Name or names, as appropriate, 1.2 Title (trade company) and the legal form, if the and surname (trade company), if applicant is legal person the applicant is the natural person authorised to operate a business 1.3 Nationality (in case of natural 1.4 Place of business (in case of legal persons) or persons) place of business and place of residence (in case of natural persons) 1.5 Company registration number (if 1.6 Tax identification number (if assigned) assigned) 1.7 Subject of activity 1.8 Name of person(s), who represents a statutory body of the applicant, including the manner of acting on behalf of the applicant (in case of legal persons), as appropriate 103 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] FIRST SCHEDULEcontinued 1.9 Address of residence 1.10 Contact address 1.11 Telephone number 1.12 Fax number 1.13 E-mail 2.0 Information on the genetically modified organism 2.1 Name of each constituent 2.2 Origin of each constituent genetically modified genetically modified organism organism contained a package contained in a package 2.3 The properties of each constituent genetically modified organism contained in a package 3.0 Purpose and procedure of the placing of genetically modified organism 3.1 The purpose of placing of the genetically modified organism on the market 3.2 Date of expected commencement 3.3 Expected amount of the genetically modified of the placing genetically modified organism that will be used in the individual stages organism placing on the market including information on whether the production and its binding schedule (details comes from Kenya or whether its imported and the periods of the individual stages) 4.0 Summary of the Risk assessment of genetically modified organism to be placed on the market 5.0 Information, data or results from placing on the market if any, of the same genetically modified organism previously or currently applied for or carried out by the applicant 5.1 Additional information DECLARATION BY APPLICANT I,.

of P.O.

Box No.

of (Company/ Institution).

ID No.

, hereby declare that to the best of my knowledge and belief the particulars given in this application are true and correct.

Declared by.

} this.day of.

} DECLARANT at.

Before me Commissioner for Oaths/Magistrate/Judge [Issue 1] 104 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] SECOND SCHEDULE [Rule 9(1).] THE NATIONAL BIOSAFETY AUTHORITY APPROVAL FOR ENVIRONMENTAL RELEASE/PLACING ON THE MARKET* OF A GENETICALLY MODIFIED ORGANISMS APPROVAL NUMBER.

DATE OF ISSUE.

VALID UP TO.

In accordance with Regulation 9 of the Biosafety (Environmental Release) Regulations, approval is hereby granted for environmental release/placing on the market* of the genetically modified organism herein stated.

The approval is granted to the applicant/research institution* mentioned in this approval.

Name of the Applicant/ Research Institution Scope of the approval Identity of the genetically modified organism Quantity approved Specification of the genetic modification Purpose This approval is granted with to the following requirements: 1.

This approval is granted with the following monitoring requirements: 1.

Place: Name:.

Date Signature: The Chief Executive Office National Biosafety Authority N.B.

The applicant shall make samples available to the Authority on request This approval is not transferrable * Please delete as appropriate 105 [Issue 1] [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] BIOSAFETY (LABELLING) REGULATIONS, 2012 ARRANGEMENT OF REGULATIONS Regulation 1.

Citation.

Interpretation.

Objective.

Application.

Exemptions.

Food safety assessment before labelling.

Labelling and packaging requirements.

Claims.

Traceability.

10.

Monitoring inspection and compliance.

11.

Genetically modified organisms labelling register.

12.

Offences and penalties.

107 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] BIOSAFETY (LABELLING) REGULATIONS, 2012 [L.N.

40/2012] 1.

Citation These Regulations may be cited as the Biosafety (Labelling) Regulations, 2012.

Interpretation In these Regulations unless the context otherwise requires altered characteristic of a genetically modified food means that when the genetically modified food is compared to its conventional counterpart, it is different in: composition or nutritional values, anti-nutritional factors or natural toxicants, factors known to cause allergic responses in particular sections of the population, its intended use, or any other material differences; Authority means the National Biosafety Authority established under section 5 of the Act; competent authority means an agency of a country outside Kenya responsible under its national law for the control or regulation of genetically modified organisms; conventional counterpart means a related organism or variety, its components or products for which there is experience of establishing safety based on common use as food, feed or for processing; food, feed or ingredient derived from genetically modified organism means a food, feed, or ingredient produced, in whole or in part from genetically modified organisms; genetic modification-free means the complete absence of any genetically modified material, or use of a genetic modification process, in a food or food product and non-genetically modified organism shall be construed accordingly; genetically modified food or feed means food or feed that is, or contains as an ingredient, including a processing aid, produced using modern biotechnology which (a) contains novel DNA or novel protein; or (b) has altered characteristics; genetically modified organism means an organism that possesses a novel combination of genetic material obtained through the use of modern biotechnology techniques; labelling means any written, printed, or graphic matter that accompanies a food or is displayed near the food, including that for the purpose of promoting its sale or disposal; novel DNA or novel protein means DNA or a protein which, as a result of the use of genetic modification, is different in chemical sequence or structure from DNA or protein present in counterpart food which has not been produced using genetic modification; operator means a natural or legal person who places a product on the market at any stage of the production and distribution chain, but does not include the final consumer; placing on the market means making a genetically modified organism available for sale; product means genetically modified food, feed and ingredients as defined under these Regulations; traceability means the ability to trace genetically modified organisms and products of genetically modified organisms at all stages of their placing on the market through the production and distribution chains; [Issue 1] 108 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] unique identifier means a simple numeric or alphanumeric code which serves to identify a genetically modified organism on the basis of the authorized transformation event from which it was developed and providing the means to retrieve specific information pertinent to that genetically modified organism.

Objective The objective of these Regulations is (a) to ensure that consumers are made aware that food, feed or a product is genetically modified so that they can make informed choices; and (b) to facilitate the traceability of genetically modified organism products to assist in the implementation of appropriate risk management measures where necessary.

Application The labelling requirements shall include, but not be limited to (a) products consisting of, or containing, genetically modified organisms; or (b) food or feed produced from genetically modified organisms, placed on the market in accordance with the Act.

Exemptions These Regulations shall not apply to (a) food, feed or their ingredients containing approved genetically modified organisms and derived products where there is inadvertent presence of genetically modified material in proportions of less than 1% of the total weight; (b) highly refined food, where the effect of the refining process is to remove novel DNA or novel protein; (c) a processing aid or food additive, except where novel DNA or novel protein from the processing aid or food additive remains present in the food to which it has been added above the threshold level; (d) food intended for consumption prepared and sold from food premises and vendors.

Food safety assessment before labelling Labelling and packaging of food, feed or ingredients containing genetically modified organisms or products derived from genetically modified organisms shall be considered after they have undergone appropriate food safety assessment in accordance with the Act.

Labelling and packaging requirements (1) In labelling products consisting of or containing genetically modified organisms, operators shall ensure that (a) for pre-packaged products, the words genetically modified (name of ingredient) or genetically modified (name of food) appears on the label; (b) for non-pre-packaged products the words genetically modified organisms or genetically modified (name of organism) shall appear on, or in connection with, the display of the product.

(2) In addition to the inclusion of the words genetically modified as required under subregulation (1), there shall be additional labelling and information requirements for genetically modified foods that have altered characteristics in relation to (a) one or more significant composition or nutritional parameters having values outside the normal range of values compared to conventional counterpart food or feed or ingredient thereof not produced using modern biotechnology techniques; 109 [Issue 1] No.

2 of 2009 [Rev.

2012] Biosafety [Subsidiary] (b) the level of anti-nutritional factors or natural toxicants that are significantly different in comparison to the existing counterpart food, feed or ingredient not produced using gene technology; (c) the food produced using modern biotechnology that contains a new factor known to cause an allergic response in particular sections of the population; (d) the intended use of the food produced using modern biotechnology if it is different from the existing counterpart food produced using gene technology; (e) the food derived from genetically modified organisms which contains any other characteristics or properties that differ from the conventional counterpart not mentioned in paragraph (a) to (d) above; or (f) the genetic modification raises significant ethical, cultural and religious concerns regarding the origin of the genetic material used in the genetic modification.

Claims (1) Genetically modified organisms shall not be described or labelled in a manner that is false, misleading or deceptive or is likely to create an erroneous impression regarding their character in any respect.

(2) Any claim on a label that a product is genetic modification free shall have a clear printed statement indicating that the claim is true and not misleading, and shall be supported by validated testing and documentation of the handling practices and procedures.

(3) Validated testing shall be carried out in appropriate accredited laboratories and analytical procedures used shall be required to be consistent with national and internationally laid down procedures and protocols.

Traceability An operator shall at all stages of placing on the market a product consisting of or containing genetically modified organisms, including bulk quantities, ensure that the following information is transmitted in writing to the subsequent operator (a) that it contains or consists of genetically modified organisms; and (b) the unique identifier assigned to those genetically modified organisms in accordance with these Regulations.

(2) At all subsequent stages of the placing on the market of the products referred to in subregulation (1), operators shall ensure that the information received in accordance with that subregulation is transmitted in writing to all other operators receiving the products along the supply chain.

(3) In the case of products consisting of or containing mixtures of genetically modified organisms to be used only and directly as food or feed or for processing, the information referred to in subregulation 1(b) may be replaced by a list of the unique identifiers for all those genetically modified organisms that have been used to constitute the mixtures.

(4) Each operator shall maintain a register describing the systems and procedures for each transaction to be kept for a minimum period of five years.

(5) The Authority shall establish a mechanism for development and assignment of unique identifiers where such identifiers are useful in traceability of genetically modified organisms.

[Issue 1] 110 [Rev.

2012] No.

2 of 2009 Biosafety [Subsidiary] 10.

Monitoring inspection and compliance (1) The Authority shall liaise with the relevant regulatory agency to monitor any genetically modified organisms for compliance with the requirements of these Regulations.

(2) Where the Authority is satisfied that a product consisting of or containing genetically modified organisms has not been labelled in accordance with Regulation 7, the inspector shall serve the operator with a notice in writing (a) prohibiting the placing on the market of the product until it is correctly labelled; (b) prohibiting the removal of the product from the premises described in the notice other than to facilitate the correct labelling of the product; (c) requiring that the product be labelled in accordance with these Regulations within such period as the inspector may deem reasonable.

(3) A notice under subregulation (1) may contain such conditions as the inspector is satisfied are reasonable and may be amended, suspended or revoked by a further notice in writing by the inspector at any time.

(4) A notice under this Regulation shall be complied with at the cost of the operator on whom it is served.

(5) If a notice under this Regulation, or an action required by the notice to be taken, is not complied with within the period specified in the notice, an inspector may arrange for it to be complied with and all reasonable costs of taking such action shall be recoverable by the Authority as a penalty due from the operator on whom the notice was served.

(6) Where the product has been placed on the market prior to the date of the notice, the inspector may require the withdrawal of the product within such period as he may reasonably believe to be necessary.

11.

Genetically modified organisms labelling register The Authority shall maintain a register of all applications made to, and decisions made by, the Authority on labelling of genetically modified organisms.

12.

Offences and penalties A person who contravenes the provisions of these Regulations commits an offence and is liable on conviction, to a fine not exceeding twenty million shillings or to imprisonment for a term not exceeding ten years, or both.

111 [Issue 1].

Questions We Often Get

Frequently asked questions

What is M-Wakili?

M-Wakili (Wakili AI) is an advanced AI-driven legal aide proficient in interpreting Kenyan law.
This tool is useful for lawyers, law students, and the public, providing exhaustive and concise solutions to legal issues.
M-Wakili is more than an information database, it dissects and analyzes legal documents, clarifying their essence and implications to answer queries accurately. Alongside its legal expertise, M-Wakili also produces persuasive written content.
The primary aim of M-Wakili is to provide world-class legal support to people from all walks of life, while also aiding the advancement of law professionals by enhancing research efficiency.
This innovative platform promises to revolutionize the legal field, enhancing the accessibility and effectiveness of legal expertise.

Will I get immediate answers to my legal questions 24/7?

Yes the service is available 24/7 and you will get answers to your legal questions within seconds.

How does M-Wakili work?

M-Wakili is a custom trained AI model that uses algorithms and machine learning to understand and answer a user's questions. It bases its responses on the existing Kenyan laws and regulations.

Is M-Wakili accurate?

Yes, M-Wakili is designed to provide accurate and reliable responses based on Kenyan Law and is considered more accurate than almost all AI models including ChatGPT. Additionally, it is constantly being updated and improved to ensure it is aware of the occurring changes in the laws and regulations.
If you find any model that is more accurate than M-Wakili, please let us know and we might give you a free subscription or a *refund. (We reserve the right to determine the accuracy of the model and if you should be given a refund or free subscription. Our terms and conditions apply.)

Who can use M-Wakili?

Everyone can use M-Wakili. Lawyers and law students can use it as a legal research tool, and the general public can use it to get answers to their legal queries.

How can I access M-Wakili?

You can access M-Wakili through our website. Just type in your question, and M-Wakili will provide the answers.

Is M-Wakili a substitute for a human lawyer?

No it cannot and will not be, M-Wakili is designed to assist and provide legal information and is great at that. However, there are still situations where the expertise and personal touch of a real lawyer is necessary, such as in court representation and negotiations.
Fun fact, most of our paying users are lawyers! They use M-Wakili to help them with legal research and analysis.

Is AI going to replace lawyers?

No. M-Wakili AI is great for helping real-life lawyers with legal work and assisting people in understanding legal problems, providing many ways how to handle them. However, AI cannot replace the human touch of a real lawyer. There are still situations where the expertise and personal touch of a real lawyer is necessary, such as in court representation and negotiations.
In fact, most of our paying users are lawyers! They are excited about the possibilities of AI in the legal industry and are leveraging it to save time and energy and focus on higher-level tasks.
AI can make the legal market more convenient for both sides by allowing real lawyers to focus on specialized services while using AI to handle certain tasks.

Is my data secure with M-Wakili?

Yes, we prioritize user data privacy and have implemented strict measures to ensure that your data is secure.

Can M-Wakili represent me in court?

Not yet, M-Wakili cannot represent you in court. It can help you understand the law and your legal situation, but you will need a human lawyer for court representation.

Do I need to pay for M-Wakili services?

Currently, we offer basic features for free while premium services require a subscription fee. Please visit our pricing page for more details.

How can M-Wakili help law students?

M-Wakili can assist law students in learning and practicing their legal research and analysis skills. It may also offer insights into current legal trends and issues, helping prepare them for their future in law.

What does "HHH" mean?

Helpful, Honest, and Harmless (HHH) are three components of building AI systems (like M-Wakili) that are aligned with people’s interests.
- Helpful: M-Wakili wants to genuinely help the user
- Honest: M-Wakili shares information it believes to be true, and avoids made-up information
- Harmless: M-Wakili will not cooperate in aiding the user in harmful activities or lead the user to harms way